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ABSTRACT 
 
 
Age-related physiological changes in the gastrointestinal tract, as well as modification in lifestyle, 
nutritional behaviour, and functionality of the host immune system, inevitably affect the gut 
microbiota. The study presented here is focused on the application and comparison of two different 
microarray approaches for the characterization of the human gut microbiota, the HITChip and the 
HTF-Microb.Array, with particular attention to the effects of the aging process on the composition 
of this ecosystem. 
By using the Human Intestinal Tract Chip (HITChip), recently developed at the Wageningen 
University, The Netherland, we explored the age-related changes of gut microbiota during the 
whole adult lifespan, from young adults, through elderly to centenarians. We observed that the 
microbial composition and diversity of the gut ecosystem of young adults and seventy-years old 
people is highly similar but differs significantly from that of the centenarians. After 100 years of 
symbiotic association with the human host, the microbiota is characterized by a rearrangement in 
the Firmicutes population and an enrichment of facultative anaerobes. The presence of such a 
compromised microbiota in the centenarians is associated with an increased inflammation status, 
also known as inflamm-aging, as determined by a range of peripheral blood inflammatory markers. 
In parallel, we overtook the development of our own phylogenetic microarray with a lower number 
of targets, aiming the description of the human gut microbiota structure at high taxonomic level. 
The resulting chip was called High Taxonomic level Fingerprinting Microbiota Array (HTF-
Microb.Array), and was based on the Ligase Detection Reaction (LDR) technology, which allowed 
us to develop a fast and sensitive tool for the fingerprint of the human gut microbiota in terms of 
presence/absence of the principal groups. The validation on artificial DNA mixes, as well as the 
pilot study involving eight healthy young adults, demonstrated that the HTF-Microb.Array can be 
used to successfully characterize the human gut microbiota, allowing us to obtain results which are 
in approximate accordance with the most recent characterizations. Conversely, the evaluation of the 
relative abundance of the target groups on the bases of the relative fluorescence intensity probes 
response still has some hindrances, as demonstrated by comparing the HTF.Microb.Array and 
HITChip high taxonomic level fingerprints of the same centenarians.    
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1. 
INTRODUCTION 
 
 
1.1 The human gut microbiota 
 
     1.1.1 Overview 
An enormous number of microorganisms are known to colonize and form complex communities, or 
microbiota, at various sites within the human body. In fact, humans have been proposed to be 
“metaorganisms” consisting of 10-fold greater numbers of bacterial than animal cells that are 
metabolically and immunologically integrated. The gastrointestinal tract harbors the largest and 
most complex bacterial ecosystem in the human body (Hattori and Taylor, 2009; Neish, 2009). An 
increasing gradient in bacterial concentration characterizes the human gastrointestinal tract, from 
stomach, to jejunum, ileum and colon, where the concentration peaks to 10
11
-10
12
 bacterial cells per 
gram of stool (Ley et al, 2006a; Leser and Molbak, 2009). 
Shaped by millennia of co-evolution, host and bacteria have developed beneficial relationships, 
creating an environment for mutualism. The collective genome of the gut microbial community is 
called “microbiome” and contains more than 100 times the number of genes in the human genome 
(Backhed et al, 2005). The microbiome endows human hosts with physiological attributes they did 
not evolve on their own, including enhanced metabolic capabilities, such as hydrolysis of complex 
plant polysaccharides, synthesis of certain vitamins and production of short chain fatty acids 
(SCFA)  (Hooper et al, 2002). Other benefits provided by the gut microbiota are involved in the 
development and maintenance of the immune system homeostasis (Round and Mazmanian, 2009) 
and in the development and survival of the gut epithelium (Neish, 2009). Finally, the gut microbiota 
exerts a right of “first occupancy” precluding other microorganisms, particularly pathogens, from 
invading the occupied niches (Sansonetti and Medzhitov, 2009).   
The total diversity of a healthy adult gut ecosystem is generally reported around 1,000-1,200  
species-level phylogenetic types, called “phylotypes”, defined as group of 16S sequences with a 
certain level (97-99%) of similarity (Eckburg et al, 2005; Rajilic-Stojanovic et al, 2007; Xu et al, 
2007). However, some recent molecular studies approximated the diversity of the gut microbiota to 
more than 10,000 phylotypes (Frank et al, 2007; Tap et al, 2009). Only a small percentage of these 
gut inhabitants correspond to fully characterized bacterial isolates, whereas 75-82% is estimated to 
remain uncultured (Eckburg et al, 2005; Flint et al, 2007; Rajilic-Stojanovic et al, 2007). 
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This remarkable diversity (Fig. 1.1) is confined largely to very few divisions of bacteria and one 
member of Archaea, Methanobrevibacter smithii. The vast majority (90-99%) of the bacterial 
inhabitants belongs to Firmicutes and Bacteroidetes, with the dominant Firmicutes (50-80%) 
primarily composed of bacteria belonging to the Clostridium clusters XIVa and IV (Eckburg et al, 
2005; Ley et al, 2006b; Turnbaugh et al, 2006; Frank et al, 2007; Armougom and Raoult, 2008; 
Dethlefsen et al, 2008; Tap et al, 2009). Other phyla represented in the human gut are 
Actinobacteria (3-15%), Proteobacteria (1-20%), and Verrucomicrobia (0.1%) (Frank et al, 2007; 
Andersson et al, 2008; Hattori and Taylor, 2009; Tap et al, 2009). The procaryotic phyla 
Fusobacteria, Cyanobacteria, Spyrochaetes, and Lentisphaerae, as well as  several eukaryotic fungal 
species (Candida, Aspergillus and Penicillium), were also reported as gut inhabitants in very small 
percentages (Rajilic-Stojanovic et al, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 16S rRNA-based phylo-
genetic tree of the distinct phylo-types 
that have been found in the human 
gastrointestinal tract. The Firmicutes 
phylum is divided in the different 
Clostridium clusters, as described by 
Collins et al (1994). The relative 
proportion of phylotypes that 
correspond to cultured representatives 
is indicated by different darkness of the 
filling: black fills indicates species 
detected in cultivation independent 
studies, while white indicates species 
detected in cultivation based studies. 
Numbers of distinct phylotypes are 
given for each phylogenetic group. 
(Rajilic-Stojanovic et al, 2007). 
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The adult-like structure of the gut microbiota summarized above is established after the first year of 
life, during which the gut ecosystem progresses from sterility to extremely dense colonization 
(Palmer et al, 2007). Through healthy adulthood, the bacterial density and diversity in the gut  
remains relatively stable over time, in spite of the continuous flow of intestinal content, reflecting 
the ability to maintain a high degree of homeostasis (Vanhoutte et al, 2004; Leser and Molbak, 
2009). The adult microbiota shows an astonishing individual variability, and it is considered as 
unique as a fingerprint in terms of species and strains composition (Zoetendal et al, 1998; Eckburg 
et al, 2005; Ley et al, 2006a). Age, diet, lifestyle, and geographic origins influence the composition 
of the gut microbiota, but studies involving human adults with different relatedness, from 
genetically unrelated people to monozygotic twins, demonstrated that the impact of genotype  may 
also be significant in shaping the gut bacterial ecosystem (Zoetendal et al, 2001; Lay et al, 2005; 
Mueller et al, 2006, Khachatryan et al, 2008). 
Despite the remarkable host specificity in the gut community membership, a high degree of 
conservation in its expressed functions and metabolites has been reported (Mahowald et al, 2009). 
This suggests that the gut microbiota may be characterized by a marked “functional redundancy” to 
ensure that the key functions of the microbial community remain unaffected by the individual 
variability in terms of species composition (Gill et al, 2006). The existence of a “human core gut 
microbiome”, defined as those genes which are common to the gut microbiomes of all or the 
majority of humans, has been hypothesized to be responsible for the functional stability of the gut 
microbiota (Turnbaugh and Gordon, 2009). On the contrary, a “human core gut microbiota”, 
defined as a number of species which are common to all humans, could hardly be defined, since 
different combinations of species could fulfil the same functional roles (Tschop et al, 2009, 
Turnbaugh et al, 2009). Aside to the core, the set of genes which are present in smaller subsets of 
human constitutes the “human variable microbiome” (Fig. 1.2). This impressively wide variation 
from the core is the result of a combination of host-specific factors, such as genotype, physiological 
status, host pathologies, lifestyle, diet, environment, and the presence of transient populations of 
microorganisms that cannot persistently colonize the human gut. In return, core and variable 
components of the the human microbiome influence different aspects of the human health, 
including nutrient responsiveness and immunity (Turnbaugh et al, 2007). 
Major alterations in the gut microbiota structure, and consequently in the gut microbiome, affect 
human physiology, health status and disease susceptibility. The ecological disorder of the bacterial 
community is called “dysbiosis”, and affects the structure of the microbiota at the level of 
order/phylum. For instance, changes in the relative proportion of Firmicutes and Bacteroidetes are 
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always detected in metabolic disorders, such as obesity (Ley et al, 2006b; Turnbaugh et al, 2009; 
Turnbaugh and Gordon, 2009), type 1 diabetes (Wan et al, 2008), and inflammatory bowel diseases 
(IBD) (Frank et al, 2007; Sartor, 2008a; Sartor, 2008b). Imbalanced microbiota and bacterial 
overgrowth are also  reported in irritable bowel syndrome (IBS), which is a very common, probably 
stress-related, functional gastrointestinal disorder (Kassinen et al, 2007; Othman et al, 2008). 
Being involved in so many aspects of human physiology and disease, the microbiota (and 
microbiome) represents a new frontier of human biology and medicine, as well as a potential drug 
target, in which new strategies for the maintenance of human health may be found (Hattori and 
Taylor, 2009). 
 
 
 
 
Fig. 1.2  A super-organismal view of the human microbiome. A subset of microbial genes may be found in most healthy 
human beings (core microbiome) whereas variable components are presents only in specific ethnic groups, age groups, 
geographic locations, or associated with specific dietary patterns or disease status (Turnbaugh et al, 2007;  Preidis and 
Versalovic, 2009). 
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 1.1.2 Gut microbiota and immune system 
The coevolution of human host and its microbiota had a particularly strong impact on the immune 
system, which had to develop the ability to discriminate between the tolerated resident commensal 
microbiota and invasive pathogens, to whom it must respond. Immunological abnormalities 
observed in germ-free model animals showed how strong the impact of the microbiota is in shaping 
the immune system, at both structural and functional level (Macpherson and Harris, 2004). Some 
symbiotic bacteria of the human gut ecosystem showed to prevent inflammatory disease during 
colonization, whereas other components of the gut microbiota showed the potential to induce 
inflammation under particular conditions (“pathobionts”). Therefore, having the potential to exert 
both pro- and anti-inflammatory responses, the gut microbiota composition is likely to be linked to 
the proper functioning of the immune system (Round and Mazmanian, 2009). 
In healthy condition, the cross talk between the bacteria and both the mucosal and the systemic 
immune system ends up in a low-level physiological inflammatory response, which is the result of 
the balance between tolerance and reactivity. A dysbiotic microbiota can alter this delicate and 
complex equilibrium, leading to a switch from physiological to pathological inflammation and 
immune response, characterized by unrestrained immune cell activation and pro-inflammatory 
cytokines production. In particular, a dysbiotic, or so-called “colitogenic” microbiota, is often 
associated with the pathogenesis of IBD. Since no infectious organisms have been identified as 
causative agents of IBD, it has been suggested that the target of the chronic inflammation may not 
be pathogens but overrepresented pathobionts. Although it is not clear whether dysbiosis is the 
cause or the effect of the disease, gut microbiota alterations may be a factor underlying the 
development of the disease in genetically predisposed individuals (Sartor, 2008a; Round and 
Mazmanian, 2009; Sansonetti and Medzhitov, 2009). 
Inflammation processes induced in the gut mucosa by a dysbiotic microbiota are also connected to 
the pathogenesis of colorectal cancer, a major disease of the Western “over-seventy” population.  
Even if the complex interplay between microbiota, host and cancer still has to be completely 
understood, it is known that chronic inflammation supports carcinogenesis by inducing gene 
mutations, inhibiting apoptosis or stimulating angiogenesis and cell proliferation. Moreover, colonic 
microorganisms can promote DNA damages in epithelial cells by producing carcinogenic, co-
carcinogenic and pro-carcinogenic molecules (Candela et al, manuscript in preparation).   
Finally, the cross-talk between the host immune system and the gut microbiota may also be 
involved in the physiology of allergies and autoimmune pathologies, such as celiac disease and type 
1 diabetes (MacDonald and Monteleone, 2005; Varaala et al, 2008; Wen et al, 2008; Tang, 2009). 
Autoimmunity is rapidly becoming a major health problem in the industrialized countries. It has 
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been hypothesized that modern health-care strategies, such as caesarian section, formula-based diet, 
improved hygiene, vaccinations, and use of antimicrobials in infants, may produce deviations in the 
normal development of the human microbiota. The consequent increased probability of dysbiosis 
can alter the development of the immune system, predisposing the individuals to various immune 
related diseases later in life (“hygiene hypothesis”) (Round and Mazmanian, 2009). 
 
 1.1.3 Probiotics and prebiotics 
The increased understanding of the impact of the gut microbiota on human health resulted in 
attempts of manipulate its composition by the use of probiotics and prebiotics, both in prophylactic 
and therepeutic perspectives. 
Probiotics are defined as “live microorganisms which, when administered in adequate amounts, 
confer a health benefit on the host” (Guarner and Malagelada, 2003). The concept of “probiotics” 
dates back over 100 years, when Metchnikoff suggested that the use of living bacteria in fermented 
milk products could improve health by detoxifying putrefactive substances (Metchnikoff, 1907). 
However, only recently scientific knowledge and tools have become available to evaluate their 
potential in improving health, and preventing and treating diseases, allowing us to find out many 
“candidate probiotics” among bacteria, with different actions in different disease status (Reid et al, 
2003; Chermesh and Eliakim, 2006). 
Effectiveness and safety are prerequisites for microorganisms to be considered probiotics. 
Moreover, they should pass through the upper gastrointestinal tract unaffected by bile acids and 
proteolytic enzymes, and enter the small bowel. Their main beneficial effects are to function as the 
first barrier to pathogenic organisms by adherence, to produce substances that have antimicrobial 
effects, and to stimulate the immune processes in the host (Floch and Martin, 2005; Chermesh and 
Eliakim, 2006). The most employed probiotics belong to the genera Lactobacillus and 
Bifidobacterium, but other genera, including Escherichia, Enterococcus, Bacillus and 
Saccharomyces, are also used, based on documented efficacy through clinical studies (Gibson et al, 
2004). 
Prebiotics are more a recent concept, firstly defined 10 years ago. They are chemical substances, 
usually oligosaccharides, acting as substrates specifically for the host’s autochtonous probiotic 
bacteria, and thus promoting their growth. Prebiotics are selected as being non-digestible by the 
host and non-metabolizable by non-probiotic gut bacteria, but stimulating for bifidobacteria and 
lactobacilli (Gibson et al, 2004; Hamilton-Miller, 2004). 
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       1.2. The characterization of the gut bacterial ecosystem 
 
 1.2.1 From cultivation to molecular techniques 
The characterization of the community composition is the first step in the study of a complex 
bacterial  ecosystem. The gut microbiota has been intensively investigated by anaerobic culture 
techniques, but it is well known by now that culture based methods provide only an incomplete 
picture of the overall diversity of the microbiota (Rajilic-Stojanovic et al, 2007; Zoetendal et al, 
2008). Additionally, culture based methods are laborious, time-consuming, and prone to statistical 
and methodological errors. Thus, in the last decade many molecular tools have been developed, 
allowing faster and more accurate investigations of complex microbial ecosystems. 
The most efficient culture-independent strategies for exploring microbial biodiversity are based on 
the 16S ribosomal RNA (rRNA) gene sequence. The 16S rRNA gene (Fig 1.3) consists of about 
1,500 nucleotides and contains regions conserved among all the bacteria, interspersed with 9 
regions (V1 to V9) in which the sequences are variable among bacterial phylotypes (Tannock, 
1999). Sequencing of the 16S rRNA genes has resulted in more than one million small subunit 
rRNA entries, which are available through databases such as GeneBank, EMBL, Ribosomal 
Database Project (RDP). 
 
Fig. 1.3  E. coli 16S rRNA secondary structure. Position of the nine variable regions (V1 to V9) is indicated. 
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Common 16S-based approaches include cloning and sequencing of a large number of 16S rRNA 
genes, which gives significant information about the identity of uncultured bacteria, but is 
laborious, expensive and hardly quantitative. Several so-called “fingerprinting techniques” are more 
appropriate to study a complex bacterial community, although they are only semi-quantitative. They 
are used for monitoring community shifts (e.g. in response to dietary treatments), following the 
microbiota composition through time, or comparing individuals. The most important fingerprinting 
techniques are denaturing/temperature gradient gel electrophoresis (D/TGGE), single strand 
conformation polymorphism (SSCP) and terminal-restriction fragment length polymorphism (T-
RFLP).   
Frequently applied culture-independent approaches to quantify bacterial cells in environmental 
samples are the real time-PCR and the Fluorescent In-Situ Hybridization (FISH). These techniques 
use 16S rRNA-targeted primers and probes, respectively. Specific primer sets and probes have been 
developed to quantify bacteria belonging to various groups, such as Eubacterium rectale - 
Clostridium coccoides group (approximatively corresponding to the Clostridium cluster XIVa), 
Clostridium leptum group (Clostridium cluster IV), Bacteroides/Prevotella group, Bifidobacterium, 
Lactobacillus/Enterococcus group, Veillonella, Atopobium, and Ruminococcus group. When 
fluorescent probes are used, bacterial counts can be performed by using microscopy or flow 
cytometry (Zoetendal et al, 2004). The disadvantage of these quantitative techniques resides in the 
fact that primers and probes can be designed and validated only for bacterial groups which are 
known, and whose 16S rRNA has been sequenced. Moreover, the study consists in one experiment 
for each probe or primer set. 
More recently, the microarrays technology has been applied to the study of the diversity of complex 
ecosystem. Diversity microarrays allow identification of bacterial species in unknown samples. 
They have recently been introduced in microbial ecology for environmental studies of 
phylogenetically diverse microbial groups. In the majority of the cases they are based on the 16S 
rRNA gene, but microarrays based on other functional genes (rpoB, recA, gyrB, groEL, and atpD) 
can be used to distinguish between closely related bacteria, having a resolution below the species 
level. For instance, members of the superfamily of γ-proteobacteria, such as Escherichia coli, 
Salmonella, and Shigella can be distinguished by using a gyrB (B subunit of DNA gyrase) based 
diversity microarray (Kakinuma et al, 2003). The first effort in developing a diversity microarray 
specific for the intestinal tract consisted in 60 probes, targeting 20 bacterial species predominant in 
human intestine (Wang et al, 2002). 
The development of diversity microarrays during the last years has been aiming at the improvement 
of the coverage of the complete human intestinal microbiota. Since our knowledge of the gut 
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microbiota composition is becoming wider and more detailed, it is necessary to increase the number 
of probes spotted on the intestinal diversity microchips. In 2006, Palmer and coworkers developed a 
powerful diversity microarray, based on the 16S rRNA sequence, able to detect and quantify 
bacterial species up to 0.1% of fractional abundance. A more comprehensive and improved diversity 
microarray, containing more than 9,000 taxonomically specific probes, was designed by the same 
research group and used to profile the gut microbial community of human infants, aiming the 
investigation the possible origins of the infant microbiota (Palmer et al, 2007). More recently, a 
human intestinal microbiota phylogenetic microarray, based on the Affymetrix GeneChip platform, 
containing probes for 775 different bacterial phylotypes, was developed by Paliy et al (2009). The 
microarray was used in a pilot study, detecting differences in the microbiota composition of adults 
and children. In conclusion, microarray technology, with its ability to detect and measure thousands 
of distinct sequences simultaneously, has been recognized as a valuable tool to explore and 
systematically characterize complex microbial communities. 
 
 1.2.2 The HITChip technology 
The Human Intestinal Tract Chip (HITChip) is a 16S based diversity microarray designed to 
comprehensively cover the diversity of the human gut microbiota reported in culture-dependent and 
culture-independent studies. It has been developed by Rajilic-Stojanovic et al (2009), on the basis 
of an ecosystem-specific curated database, containing 16,000 human intestinal 16S rRNA 
sequences. The HITChip is manifactured by Agilent Technologies and contains approximately 
4,800 in situ synthesized, tiling oligonucleotide probes with a narrow range of melting 
temperatures. Each of the 1,140 targeted microbial phylotypes (<98% identity) is represented by 
multiple probes designed on the basis of the V1 and V6 hyper-variable regions of the 16S rRNA. 
The tiling approach consists in the design of series of nucleotide probes (in this case, 6 overlapping 
probes) which cover the entire sequence of the V1 and V6 regions, so that each phylotype is defined 
by a probe set, instead of a single probe. The specificity of each probe was determined by in silico 
hybridization against the human intestinal microbiota 16S rRNA database (Rajilic-Stojanovic et al, 
2007). Probes were categorized at three levels of specificity: level 1 (phylum/order like sequence 
groups), level 2 (genus-like groups, >90% similarity), and level 3 (>98% similarity). Therefore, 
although all probes were designed to target unique phylotypes, some of them were a posteriori 
assigned to different nodes in the phylogenetic tree. Briefly, the HITChip approach consists in 
amplifying by universal PCR the total 16S rRNA genes  from the DNA extracted from feces (or 
other human gut samples), than a fluorophor-labelled rRNA is obtained and hybridized on the array. 
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The hybridization profiles of each sample provides an identification and a relative quantification of 
the phylogroups present in the sample (Fig. 1.4).   
HITChip was used in a pilot study involving five adults and five elderly, and confirmed previous 
findings that the adult fecal microbiota is highly individual specific and relatively stable over time 
(Rajilic-Stojanovic et al, 2009). This technique was also used in a clinical trial aiming the study of 
effects of a probiotic cocktail on people with IBS (Kajander et al, 2008). 
 
 
 
Fig. 1.4  Schematic representation of the HITChip approach for the characterization of a complex bacterial ecosystem. 
 
 
 1.2.3 Pyrosequencing: a massive sequencing approach 
Even if diversity microarrays are a very straight-forward techniques to use for comparative 
community profiling, faster and cheaper than high-coverage sequencing, they can only detect taxa 
that are covered by the reference sequences. In recent years, next generation sequencing 
technologies have been developed, allowing the massive sequencing of a vast numbers of (partial) 
16S rRNA genes from many complex bacterial ecosystems, at much lower cost than Sanger's 
capillary electrophoresis method (Claesson et al, 2009). 
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Pyrosequencing is a sequencing-by-synthesis method, based on the detection of the pyrophosphate 
release occurring at the nucleotide incorporation during the sample amplification. The technique 
was developed by Nyrén and Ronaghi at the Royal Institute of Technology in Stockholm (Ronaghi 
et al, 1998). The newest application of the pyrosequencing technology, the 454 FLX Sequencing 
System, consists in using a PicoTiterPlate device in which hundreds of thousands of beads, each 
carrying millions of copies of a unique single strand DNA molecules, are sequenced in parallel. 
Nucleotides are flowed sequentially in a fixed order across the plate, and when a nucleotide 
complementary to the template is flowed into a well the polymerase extends the DNA strand. The 
incorporation of one (or more) nucleotide results in a reaction that generates a light signal, whose 
intensity is proportional to the number of nucleotides incorporated (www.454.com). 
Thanks to the 454 Life Science, a biotechnology company specialized in this high-throughput 
sequencing method, this technology is being successfully applied to many life science field, 
including the characterization of the gut ecosystem. 
A key pyrosequencing innovation, currently used in comparative studies of microbial communities, 
is multiplexing. In the so-called “barcoded pyrosequencing” each sample is tagged with a unique 
molecular barcode (a short key sequence added during PCR) and can be sequenced together with 
other barcoded samples in the same run (Hamady and Knight, 2009). The applicability of the 
barcoded pyrosequencing to the characterization of human microbial ecosystems was demonstrated 
by Andersson et al (2008), in a comparative study of the throat, stomach and fecal microbiota, and 
by Dethlefsen et al (2008), in an analysis of the effects of antibiotic treatment on the gut microbiota 
diversity. More recently, Claesson and colleagues (2009) demonstrated that pyrosequencing-based 
composition correlates with the HITChip hybridization profile of the same samples, indicating high 
robustness of both approaches. 
 
 1.2.4 The 'omics' era 
Although the techniques listed above provide an insight in the gut microbiota that was inaccessible 
with the use of traditional culturing methods, determining the function of all microbes remains a 
challenging task. One way to gain insight into potential functions and activities of microbes without 
the need of cultivation is the metagenomic approach. 
Metagenomic is defined as the study of the collective genome of an ecosystem, with attention to 
both phylogenetic and functional aspects. It is performed by extracting the total DNA from a 
microbial community, followed by cloning the DNA fragments in a suitable host using a vector 
(fosmids or bacterial artificial chromosomes). This results in a metagenomic library that can be used 
for sequence-driven and/or function-driven analysis. The first approach is used to create a catalog of 
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the genetic potential that is present in an ecosystem, whereas function-driven analyses consist in the 
transcription and translation of the genes located on the metagenome clone, and may lead to the 
discovery of novel enzyme activities. However, it has to be realized that the detection of 
genes/functions in a metagenomic library does not necessarily mean that they are functionally 
important. Therefore, other meta-'omics' approaches which use RNA, proteins, and metabolites as a 
target (Fig. 1.5) must be used to gain insight in the activity and functionality of a microbial 
community (Zoetendal et al, 2008). 
 
 
Fig. 1.5  Schematic representation of the metagenomic and other community-based 'omics' approaches. SSU rRNA, 
small subunit ribosomal RNA (Zoetendal et al, 2008). 
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         1.3 The aging process 
 
 1.3.1 Theories of aging and perspectives 
Aging has been defined as the process of intrinsic deterioration of an organism that is reflected at 
the population level as a decline in the production of offspring, and an increase in the death 
probability (Partridge and Gems, 2002). In principle, aging-associated processes are progressive 
and deleterious phenomena, common to all individuals of the species (Viña et al, 2007). 
Many theories have been proposed to explain the complex phenomenon of the aging process, 
especially in relation to the hypothesis of aging being or not an evolutionary determined 
(“programmed”) event. In Table 1 the various theories of aging are categorized as evolutionary, 
molecular, cellular and systemic (Weinert and Timiras, 2003). Evolutionary theories argue that 
aging results from a decline in the force of natural selection. Molecular and cellular theories are so 
divided depending on the level at which a factor of aging is found, whereas the system theories  
correlate the aging process to the different essential organ systems. However, in the recent views, 
aging is presented as an extremely complex, multifactorial process, that cannot be explained by a 
single cause. Different theories of aging should not be considered as mutually exclusive, but 
complementary and overlapping (Tosato et al, 2007). A more general definition says that aging is a 
stochastic process that occurs after reproductive maturation and results from the diminishing energy 
available to maintain molecular fidelity (Hayflick, 2000b). 
A new interesting theory of aging, called “remodeling theory”, has been proposed in 1995 
(Franceschi et al, 1995; Franceschi and Cossarizza, 1995; Franceschi et al, 2000c) to conceptualize 
results emerging from studies focused on the aging of the human immune system, involving healthy 
centenarians. According to this hypothesis body resources are continuously optimized during the 
aging process, and the decline in the functionality of the immune system should be considered a 
dynamic process, which includes both loss and gain of functions. In this perspective, the concept of 
“deterioration” should be replaced by “adaptation”: people who successfully age and reach 
longevity are those who better adapted to damaging agents and, in particular, immunological 
stresses. The concept of remodeling can be extended to other pathway than those involved in the 
immune system, to explain the aging phenomenon in its whole complexity. 
Finally, it has to be reminded that, with the increasing age, individual variability also increases, and 
each organ, tissue, and cell type of the body may reach different level of senescence (“aging 
mosaic” theory), making the understanding of the aging process a complex and difficult task to be 
disentangled (Capri et al, 2008; Cevenini et al, 2008). 
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Table 1.1 The major aging theories, divided by biological level. 
Theory Description 
Evolutionary  
Mutations accumulation Mutations that affect health at older ages are not selected against 
Disposable soma 
Somatic cells are mantained only to ensure continued and reproductive 
success; after reproduction soma become disposable 
Antagonist pleiotropy Genes beneficial at younger age become deleterious at older ages 
Molecular  
Gene regulation 
Ageing is caused by changes in the expression of genes regulating both 
development and ageing. 
Codon restriction 
Fidelity/accuracy of mRNA translation is impaired because of an increased 
inability to decode codons 
Error catastrophe 
Decline in fidelity of gene expression with ageing results in incresed 
fraction of abnormal proteins 
Somatic mutations DNA damages accumulation in somatic cells 
Dysdifferentiation 
Gradual accumulation of random molecular damages impairs regulation of 
gene expression 
Cellular  
Cellular senescence (Telomer 
theory) 
Phenotypes of aging are caused by an increase in frequency of senescent 
cells. Senescence may result from telomer loss (replicative senescence) or 
cell stress (cellular senescence) 
Free radicals 
Oxidative metabolism produces highly reactive free radicals that 
subsequently damage lipids, protein and DNA 
Wear-and-tear Accumulation of normal injuries 
Apoptosis Programmed cell death from genetic events or genome crisis 
System  
Neuroendocrine 
Alterations in neuroendocrine control of homeostasis results in ageing-
related physiological changes. 
Immunological 
Decline of immune functions with ageing results in decreased incidence of 
infectious diseases but increased incidence of autoimmunity 
Rate-of-living 
It assumes a fixed amount of metabolic potential for every living organism 
(live fast, die young) 
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Humans, and pet and zoo animals, are the only species in which large numbers experience aging. In 
the absence of human impact, aging simply does not occur in wild animals because of predation, 
diseases and accidents. Human aging has revealed itself because modern lifestyle allows humans to 
avoid or prevent many causes of death, not only in early life but long after reproducing. For 
instance, the improvement in the health conditions leads to the possibility to efficiently prevent 
and/or cure many diseases, and consequently to the reduction of the overall morbidity and mortality. 
Thus, aging is a consequence of the improvement in social-environmental conditions, medical 
cares, and quality of life, a sort of “artefact” of the human civilization (Franceschi et al, 2008; 
Hayflick, 1998; Hayflick, 2000a; Hayflick, 2000b). 
It has been estimated that the elderly population in developed (western) countries, defined as over-
60 years old people, will reach 2 billions by the year 2050 (Cohen, 2003), and that most babies born 
since 2000 will celebrate their 100th birthday (Christensen et al, 2009). In this perspective, it has to 
be considered that the aging population is the most susceptible to diseases and disability, and the 
most likely to be in the need of hospitalization and/or nursing care. The quality of life of this 
increasing share of the human population is going to become an imperative concern, also in relation 
of the health care cost, especially considering their high levels of health care utilization, and the 
high cost of medical care. Consequently, the goal of research on aging should not be the increase of 
human longevity regardless of the consequences, but to increase active longevity, free from 
disability and functional dependence (Hayflick, 2000b). 
  
 1.3.2 Longevity  
On the scenario of the increasing aging of the human population in developed countries, longevity, 
defined as the attainment of the extreme limits of the human life span, is becoming a reality. Life-
span is defined as the maximum numbers of years that a human being can live, whereas the life 
expectancy is the average number of years that a human can expect to live. The longest 
unambiguously documented life span is that of Jeanne Calment (France, 1875–1997), who died at 
the remarkable age of 122 years and 164 days (Abbott, 2004). 
Longevity is considered the result of the interaction between environmental factors, genetics, 
epigenetics and stochasticity, each contributing for a variable amount to the overall presentation of 
the phenotype (Candore et al, 2006). In particular, researches on twins and related individuals 
suggested that about 25% of the total variation in adult human life span can be attributed to genetic 
and epigenetic factors (McGue et al, 1993). Another 20 to 30% may be explained by the 
environment, meaning in particular life style and nutrition, but also health and socio-economical 
conditions in childhood, adult's socio-economic position, health behavior, everyday activities, 
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mental and physical health (Vaupel et al, 1998). Today, the most addressed environmental risk 
factors of the western world are cigarette smoking, alcohol consumption and overweight. 
Psychological traits and dispositions may also have some influence on longevity: whereas 
subjective well-being and happiness are related to a longer life (Idler and Benyamini, 1997), stress 
and depression may increase the risk of mortality (Huppert and Whittington, 1995). Finally, a 
contribution in attaining longevity is given by stochasticity, meaning the wide variation of life span 
of genetically identical organisms, even if reread in a constant environment. It is possible that 
longevity may be achieved by different combinations of these components, that vary quantitatively 
and qualitatively in different geographic area, according to the population-specific gene pool and 
socio-economic level (De Benedictis and Franceschi, 2006). 
At the basis of longevity are the adaptive mechanisms that the body set up to compensate and 
neutralize the adverse effects of the unrepaired damages accumulated during the whole life, leading 
to a progressive change in the human body composition and microenvironments (Ostan et al, 2008).   
Many studies highlighted that extremely long-living people (centenarians) show unusual and largely 
unexpected features for which most of the current concepts in biology and genetics are inadequate. 
In fact, the aging process allows the emerging of biological effects due to individual genetic 
differences which can be neutral or silent at younger age. This suggests that the genetic of aging and 
longevity, called “post-reproductive genetics”, may not be ruled by the classical genetic principles 
(De Benedictis and Franceschi, 2006; Capri et al, 2008). 
Centenarians may be considered the best example of extreme longevity in our species. Even if they 
are by definition very old people showing all the signs of a prolonged aging process, and 
consequently very frail, they represent a selected population in which the appearance of major age-
related diseases, such as cancer and cardiovascular diseases, has been consistently delayed or 
escaped. Part of the centenarians, in fact, are still in quite good physical and psychological health, 
categorized as “group A” by Franceschi et al (2000c), “escapers” by Evert et al (2003), and 
“exceptionals “ by Gondo et al (2006). However, centenarians were not the most robust subjects of 
their age cohort, but rather those who better adapted to the age-related changes in their body (Ostan 
et al, 2008). Although centenarians are still believed to be rare curiosity, their number is increasing 
dramatically: it has been estimated that the centenarians in the Italian population in the years 2005 
was around 7000 (Franceschi et al, 2008). For this reason, studying centenarians is a matter of 
broad biological and medical interest. 
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 1.3.3 Aging and immune system 
Immune system (IS) represents an integrated, evolutionary conserved defense network, which 
adapts over time reflecting the history of infections experienced by the organism. In this context, 
antigens constitute the major pressure for the IS evolution. Lifelong exposure to a variety of 
infectious agents for a period longer than previously encountered during human evolution, such as 
the case of long living people (80-120 years old), is one of the main forces driving the aging of IS 
(Franceschi et al, 2000a; Pawelec et al, 2005; Ostan et al, 2008). 
Immunosenescence can be defined as the age-associated decrease in immune competence which 
leads to an increased susceptibility to diseases. It is a multifaceted phenomenon, resulting from the 
adaptation of the body to the continuous challenge of bacterial and viral infections. Antigenic 
stimulation, oxidative stress, and other harmful agents are major players in this life-long 
remodelling of the IS (Franceschi et al, 1998; Larbi et al, 2008; Ostan et al, 2008). 
One of the major features of human immunosenescence is thymic involution, which is at the basis 
of the profound alterations in the T lymphocytes observed in the elderly. Particularly, a deficient 
replacing of naïve T cells lost in the periphery, resulting in the inability to maintain the breadth of 
the T cells repertoire, and an accumulation of memory and effector T cells have been observed 
(Aspinall and Andrew, 2000; Ostan et al, 2008). The innate immunity is also affected by the 
immunosenescence process, with a decrease in numbers and/or functionality of natural killer cells 
(NK), dendritic cells, and phagocytes, which is at the basis of the increased susceptibility of elderly 
to infections (Ostan et al, 2008). In particular, high NK cytotoxicity has been associated with 
healthy aging and longevity (Sansoni et al, 1993). 
The complex age-related remodelling of IS includes a profound modification within the cytokine 
network, consisting in a general increase in the production of pro-inflammatory cytokines (IL-6, IL-
1β, TNF-α). The result is a chronic, low-grade inflammatory condition named “inflamm-aging”, 
characterized by activation of macrophages and expansion of specific clones (megaclones) of T 
lymphocytes (Fagiolo et al, 1993; Franceschi et al, 2000a; Franceschi et al, 2000c; Larbi et al, 
2008). This condition goes along with a general increase in the main inflammatory markers, such as 
C-reactive protein and serum amyloid A. The overall inflammatory status potentially triggers the 
onset of the most important age-related diseases, such as cardiovascular diseases, artheriosclerosis, 
metabolic syndrome, type-2 diabetes, neurodegeneration, arthrosis and arthritis, osteoporosis, 
sarcopenia, major depression and frailty (Ostan et al, 2008). Chronic inflammation may also be at 
the basis of the pathogenesis of cancer in several organs, including stomach, liver and large intestine 
(Coussens and Werb, 2002; Condeelis and Pollard, 2006; de Visser et al, 2006). 
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All the age-related changes in the IS have a strong genetic component, as it was demonstrated by 
studies in old people and centenarians. In fact, many studies showed that the frequency of several 
variants of important genes involved in immune responses and inflammation are present at different 
frequency in long lived people with respect to young subjects. In Fig 1.6 the relevance of the 
genetic background in aging is summarized (Effros, 2003; Capri et al, 2006; Salvioli et al, 2006; 
Larbi et al, 2008). 
Centenarians represent a cohort of selected survivors, able to counterbalance the damaging effects 
of immunosenescence and inflamm-aging by activating a variety of anti-inflammatory networks, 
such as those involving IL-10 and TGF-β1, but still benefit from the functionality of the IS 
necessary to resist infectious diseases (Forsey et al, 2003; Vasto et al, 2007). Thus, it is postulated 
that centenarians are equipped with gene variants that allow them to optimize the balance between 
pro- and anti-inflammatory cytokines and other mediators involved in inflammation (Carrieri et al, 
2004; Franceschi et al, 2007). As a consequence, the study of centenarians is of great importance 
since they represent the best model to study human aging and body adaptation to the age-related 
stress phenomena at cellular, tissue, and systematic level (Franceschi et al, 1995). 
 
 
Fig. 1.6  Schematic representation of the aging of the immune system  (Larbi et al, 2008). 
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 1.3.4 Aging and gut microbiota 
The physiology of the intestinal tract is deeply affected by the aging process, as well as the 
nutritional behavior and lifestyle. Increased threshold for taste and smell (Weiffenbach et al, 1982; 
Doty et al, 1984), coupled with swallowing difficulties (Castell, 1988) and masticatory dysfunction 
caused by loss of teeth and muscle bulk (Newton et al, 1993), can lead to the consumption of a 
narrow, nutritionally imbalanced diet. Atrophic gastritis, which is a common disturbance in the 
elderly, is associated with a decreased absorption of calcium, iron and vitamin B12 (Russel, 1992). 
Furthermore, decreased intestinal motility usually results in a slower intestinal transit, which leads 
to fecal impaction and constipation (Kleessen et al, 1997); the subsequent reduced bacterial 
excretion brings to fermentation and putrefactive processes in the gut (Brocklehurst, 1972; 
Macfarlane et al, 1989). The gut functionality in the elderly is also influenced by mucosal 
immunosenescence and chronic inflammatory status (Ginaldi et al, 2001; Schmucker et al, 2003; 
Guigoz et al, 2008). 
Physiological changes in the gastrointestinal tract, as well as modification in diet, mobility, 
psychosocial stress and functionality of the host immune system, inevitably affect the balance of the 
gut microbiota, bringing to a greater susceptibility to diseases such as gastroenteritis or infection 
(van Tongeren et al, 2005; Woodmansey, 2007). Moreover, since the gut microbiota plays a role in 
the nutrient intake and energy homeostasis, changes in the microbiota could be also related to the 
loss of weight and other distinctive conditions of the elderly such as frailty, metabolic syndrome, 
diabetes and sarcopenia. 
Although this is a field of growing interest, limited researches have been focused on the changes 
which occur in the gut microbiota during the aging process. Studies involving the characterization 
of the gut microbiota in the elderly are often hardly comparable since they can have different 
purposes, such as the relation between microbiota and frailty (van Tongeren et al, 2005), the impact 
of antibiotic treatments (Bartosch et al, 2004; Woodmansey et al, 2004), or the differences between 
the gastrointestinal health status of hospitalized and non-hospitalized patients (Bartosch et al, 2004; 
Zwielehner et al, 2009). Moreover, results obtained by bacterial isolation techniques (Hopkins and 
Macfarlane, 2002; Woodmansey et al, 2004) cannot be compared with results obtained with more 
advanced techniques for the molecular characterization of the microbiota since most of the 
component of the human complex ecosystems are unculturable species (Hopkins et al, 2001; 
Rajilic-Stojanovic et al, 2007). Consequently, the definition of the gut microbiota of healthy elderly 
is a challenging task, especially since Mueller and coworkers (2006) reported striking country 
related differences in the effect of age on the gut microbiota composition. Following, the major 
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findings on the topic of age-related changes in the gut microbiota composition are summarized 
(reviewed in: Saunier and Doré, 2002; Woodmansey, 2007). 
 
A very well known effect of the aging process is the decrease of bifidobacteria in the gut 
microbiota, both in terms of abundance and species diversity (Gorbach et al, 1967; Mitsuoka, 1992; 
Gavini et al, 2001; Hopkins and Macfarlane, 2002; Saunier and Doré, 2002; Woodmansey et al, 
2004; Mueller et al, 2006). This age-effect is magnified by antibiotic treatment, hospitalization 
(Bartosch et al, 2004; Zwielehner et al, 2009) and Clostridium difficile associated diarrhea 
(CDAD), which is often a major problem in hospitalized and antibiotic treated elderly patients 
(Hopkins et al, 2001). The cause of the age-related decline in bifidobacteria may be the decreased 
ability to adhere to the intestinal epithelium showed by Bifidobacterium strains isolated from 
elderly patients, in comparison to those isolated from younger people (Ouwehand et al, 1999; He et 
al, 2001). Interestingly, the viable count of Lactobacillus, which are other well known health 
promoting bacteria, were found to increase in the elderly with respect to younger adults (Mitsuoka, 
1992; Makivuokko et al, 2010). FISH experiments showed an age-related increase of members of 
the Lactobacillus-Enterococcus group only for French and German subjects, whereas Italians and 
Swedish showed the opposite trend (Mueller et al, 2006). 
Another well established age-related effect is the increase in facultative anaerobes: streptococci, 
staphylococci, enterococci and, above all, enterobacteria (Gavini et al, 2001; Woodmansey et al, 
2004; Mueller et al, 2006; Makivuokko et al, 2010; Mariat et al, 2009). The enterobacteria group 
comprehend potentially pathogenic species, which may be the cause of infections when the host 
resistance mechanisms fail as a result of the aging process. Antibiotic treatment, hospitalization and 
CDAD are known to promote the increase of enterobacteria in the microbiota of elderly people 
(Hopkins et al, 2001; Bartosch et al, 2004; Woodmansey et al, 2004). 
Isolation studies showed a decline in viable counts of Bacteroidetes with the increasing age 
(Hopkins and Macfarlane, 2002; Woodmansey et al, 2004), but this observation was confirmed by 
FISH only when Italian adults and elderly were compared, whereas German subjects showed an 
inverse relation between age and Bacteroides amount (Mueller et al, 2006). A recent real time PCR 
study showed an increase in Bacteroides relative abundance in Austrian hospitalized elderly patients 
with respect to healthy young adults (Zwielehner et al, 2009); similar results were obtained for 
Finnish volunteers by 16S rRNA sequencing and % G+C profiling (Makivuokko et al, 2010). Thus, 
the behavior of the Bacteroides population during aging seems strongly country-dependent. 
Moreover, according to studies using 16S rRNA-based molecular techniques, a decrease in 
Bacteroidetes seems to be more strictly related to frailty condition, antibiotic treatment, 
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hospitalization and CDAD, than to the aging process itself (Hopkins et al, 2001; Bartosch et al, 
2004, van Tongeren et al, 2005). As Bacteroidetes and Firmicutes are the most dominant phyla in 
the gut, the ratio between these two groups of bacteria could be considered a more informative 
parameter of the overall status of the gut microbiota. In this context, Mariat and coworkers (2009) 
reported that the Firmicutes/Bacteroides ratio was lower in elderly people than in young adults. 
The phylum Firmicutes raises even more problems in comparing results of isolation and molecular 
techniques, because isolation techniques often referred to the genus Clostridium, whereas the 16S 
rRNA based molecular techniques use the Clostridium clusters classification proposed by Collins et 
al (1994) which is built on the 16S rRNA sequence similarity. The 16S based phylogenetic 
classification is more appropriate to describe changes in a complex microbiota, as the Firmicutes 
phylum seems to be the most affected by the cultivation bias (Rajilic-Stojanovic et al, 2007). 
Isolation studies often focus on members of the genus Clostridium known to be potentially 
pathogenic, such as C. perfringens or C. difficile, responsible for CDAD (Hopkins and Macfarlane, 
2002). Conversely, molecular characterization techniques usually consider changes in groups of 
bacteria which are major components of the gut microbiota, such as the Clostridium clusters IV and 
XIVa. These two groups are also very important as they contain the majority of the bacteria able to 
produce butyrate, a short chain fatty acid with a key role in maintaining the health of the human gut 
(Pryde et al, 2002; Louis and Flint, 2009). 
In a T-RFLP study, Hayashi and coworkers (2003) reported a decrease in bacteria belonging to the 
Clostridium cluster XIVa (also called Clostridium coccoides/Eubacterium rectale group) in healthy 
Japanese elderly. This result was confirmed for Italian and Finnish people, whereas German elderly 
showed inverse trend (Mueller et al, 2006; Makivuokko et al, 2010). The decrease of members of 
the Clostridium cluster XIVa was also related to frailty condition, hospitalization and non-steroidal 
anti-inflammatory therapy (van Tongeren et al, 2005; Tiihonen et al, 2008; Zwielehner et al, 2009). 
As for the Clostridium cluster IV (often referred to as Faecalibacterium prausnitzii group or 
Clostridium leptum group), Mueller and coworkers (2006) reported that bacteria belonging to this 
group significantly decrease along with the aging process in Italian subjects. There are no other 
studies in literature reporting changes in the Clostridium cluster IV during healthy aging, but it is 
known that hospitalization, frailty and antibiotic treatment are responsible for the decrease in the 
amount of F. prausnitzii in the gut microbiota of the elderly (Bartosch et al, 2004, van Tongeren et 
al, 2005). F. prausnitzii has recently become a matter of high interest because of its anti-
inflammatory properties in the gut environment (Sokol et al, 2008). 
In the validation study of the HITChip the gut microbiota of five adults and five elderly subjects 
from Northern Europe were compared. The obtained fingerprints confirmed that the gut microbiota 
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of young and elderly adults are different in structure and composition, especially in relation to the 
decrease of Bacteroidetes with the age and the increase of streptococci (Rajilic-Stojanovic et al, 
2009). 
 
Changes of the microbiota in terms of composition, expression of virulent factors and metabolic 
activity are detected by cells of the innate immune system, responsible for discriminating whether 
the bacterial signal represents or not a danger to the host. The gut immune system keeps under 
control a “physiological” level of inflammation at the mucosa microenvironment, preserving the 
function of the epithelium and its cross-talk with the microbiota. In old people this balance is upset 
because of the changes both in the microbiota structure and in the immune system activity, ending 
up in a localized sub-clinical inflammatory status which is typical of the intestine of the elderly. 
It has been hypothesized that immunosenescence and the decline in health promoting bacteria in the 
gut, such as bifidobacteria, may be related. In fact, several strains of Bifidobacterium exhibit 
powerful anti-inflammatory properties; thus, they may be able to restore the balance of pro- and 
anti-inflammatory cytokines production, which is at the base of the immune system regulation 
(Isolauri et al, 2001; Isolauri et al, 2002; Matsumoto and Benno, 2006). Several immuno-
stimulatory properties, such as modulation of cytokines production or adjuvant effects on T 
lymphocytes and NK cells activity, have been thoroughly demonstrated on the basis of in vitro and 
ex vivo models, for various health promoting bacteria (reviewed in: Meydani and Ha, 2000; Blum et 
al, 2002). 
More recently, Ouwehand and coworkers (2008) demonstrated that the amounts of several 
autochthonous Bifidobacterium species in the gut microbiota of elderly subjects are negatively 
correlated with the levels of the pro-inflammatory cytokine TNF-α and the regulatory cytocine IL-
10, indicating that modulation of the fecal bifidobacterial population may provide a means for 
influencing the inflammatory responses. 
 
 1.3.5 Probiotic and prebiotic in the elderly 
The aging process is often accompanied by an increased susceptibility towards infections of the 
gastrointestinal tract, which has been estimated to be 400 times higher in elderly than in younger 
adults. This observation identifies the elderly as a potential target sub-population of particular 
interest for dietary modulation of the gut microbiota, for both prophylactic and therapeutic 
management of the gut health (Hébuterne, 2003; Tuohy, 2007). In particular, the evidences of the 
decline of bifidobacteria and other health promoting bacteria in the gut of aging subjects open up 
the possibility of reversing such trend by administration of probiotics, prebiotics or symbiotics. Up 
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to the moment, trials demonstrating the application of pro/prebiotics as supplement or therapy in 
elderly people are too limited to establish their beneficial effects. 
It has been demonstrated that supplementation of probiotic Bifidobacterium strains significantly 
increases the levels of health promoting bacteria (bifidobacteria and lactobacilli) in the fecal 
microbiota of elderly (Amhed et al, 2007; Lahtinen et al, 2009; Matsumoto et al, 2009). More 
importantly, there are evidences about the effectiveness of Bifidobacterium and/or Lactobacillus 
intake in alleviating the age-related chronic constipation (reviewed in: Hamilton-Miller, 2004) and 
normalizing bowel movements in institutionalized elderly (Pitkala et al, 2007). 
As for the prebiotics, inuline supplementation was reported to be able to increase the viable count of 
bifidobacteria in constipated elderly, while the frequency of the detection of enterobacteria 
decreased with the treatment. The ingestion of inuline improved constipation in 9 out of 10 subjects 
(Kleessen et al, 1997). It has been reported that fructo-oligosaccharides ingestion (Guigoz et al, 
2002; Bouhnik et al, 2007), as well as the supplementation of a galacto-oligosaccharides mixture 
(Vulevic et al, 2008), are able to significantly increase the numbers of bifidobacteria at the expense 
of less beneficial groups. However, patients supplemented with prebiotic fibers often reported side 
effects, such as flatulence and abdominal pain. 
Bartosch and coworkers (2005) reported that a synbiotic preparation, containing inulin and two 
strains of Bifidobacterium, was able to increase the number of total bifidobacteria and lactobacilli in 
elderly individuals. Similar results were obtained by Ouwehand et al (2009) following the 
supplementation of a synbiotic containing Lactobacillus acidophilus and lactitol; this intervention 
also increased the stool frequency, which is an important parameter given the high incidence of 
constipation in the elderly. 
Even if these results seem promising, further studies are needed to determine the impact of 
functional foods on gut microbiota metabolism, pathogen resistance and intestinal function of 
elderly subjects. Moreover, therapeutic effects of pre/probiotics on age-related diseases are still to 
be determined. 
Several in vivo studies have been published investigating the possibility to influence the 
inflammatory response and immune system through probiotic/prebiotic supplementation. Clinical 
trials showed that 3- and 6-weeks interventions with Bifidobacterium lactis can have positive 
effects on the immune system of old people, such as increases of NK cells activity and monocytes 
phagocytic capacity (Chiang et al, 2000; Arunachalam et al, 2000; Gills et al, 2001a, Gills et al, 
2001b). Similar results regarding phagocytosis and NK cell activities were also described following 
supplementation of Lactobacillus rhamnosus (Sheih et al, 2001) and Lactobacillus casei Shirota 
(Takeda and Okumura, 2007) in elderly subject. A probiotic yogurt supplementation was also tested 
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on elderly affected by intestinal bacterial overgrowth, and demonstrated to be able to normalize the 
response to endotoxin and modulate activation markers in blood phagocytes (Schiffrin et al, 2009). 
A study focused on enterally fed elderly demonstrated that the level of the pro-inflammatory 
cytokine TNF- decreased in response to supplementation of fermented milk containing a probiotic 
strain of Lactobacillus; those elderly volunteers also showed a decline in the incidence of infections 
(Fukushima et al, 2007). Significant increases of phagocytosis, NK cell activity, and production of 
the regulatory cytocine IL-10 were also reported following prebiotic supplementations in elderly 
volunteers, together with a reduction in the production of pro-inflammatory cytokines (IL-6, IL-1β, 
and TNF- ) (Guigoz et al, 2002; Schiffrin et al, 2007; Vulevic et al, 2008). 
Supplementation of strains of Lactobacillus and Bifidobacterium were also positively correlated 
with the spermine and spermidine levels, which has been suggested to be associated with reduced 
inflammation (Matsumoto and Benno, 2006; Ouwehand et al, 2009). 
Restoring the homeostasis in the host-microbiota interactions in the elderly could be a way to 
improve intestinal function and help in the prevention of the immunosenescence and inflamm-aging 
processes. Anyway, confirmation of the results summarized above, and more insights in the cross 
talk between gut microbiota and immune system, are needed, especially in the perspective of the 
development of nutritional strategies targeting the gut functionality or the mucosal-host reactivity 
(Guigoz et al, 2008). Moreover, even if some of the results seem promising, parameters need to be 
established to evaluate the practical significance of the effects of pro-prebiotic treatments on the 
immune system. An interesting decrease in the duration of respiratory and gastrointestinal “winter 
infections” in elderly was reported following a 3 weeks Lactobacillus casei supplementation 
(Turchet et al, 2003), but the study is still too isolated to draw conclusions. 
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2. 
PROJECT OUTLINE 
 
 
With its global impact on the physiology of the intestinal tract, the aging process can seriously 
affect the composition of the human gut microbiota. The decreased intestinal motility results in a 
slower intestinal transit, which leads to fecal impaction and constipation (Kleessen et al, 1997). The 
subsequent reduced bacterial excretion brings to fermentation and putrefactive processes in the gut 
(Brocklehurst, 1972; Macfarlane et al, 1989), and inevitably affects the homeostasis of the bacterial 
ecosystem. Moreover, the age-related decline in the functionality of the immune system 
(immunosenescence) (Ostan et al, 2008) leads to a chronic low-grade inflammatory status 
(inflamm-aging) which can affect the intestinal gut ecosystem, undermining the balance between  
the microbiota and the gut associated immune system (Franceschi, 2007a; Franceschi et al, 2007b; 
Nova et al, 2007; Guigoz et al, 2008). Finally, considering the impact of the diet on the gut 
microbiota composition (Flint et al, 2007), changes in nutritional behavior and life style of the aged 
people concur to the age-related unbalances of the intestinal microbial community. 
The immense microbial community which constitutes the intestinal microbiota is an integral 
component of human physiology. With a role in host nutrition and protection against pathogens, this 
“microbial organ” is undeniably of primary importance for human health and well being. Thus, the 
hypothesis that age-related changes in the composition of this symbiont microbial community may 
contribute to the progression of diseases and frailty in the elderly has been ventured (Woodmansey, 
2007; Guigoz et al, 2008). 
 
The role of the gut microbiota in the aging process needs a deeper understanding, as well as its 
interaction with the host immune system. In the study presented here, we undertook to explore the 
age-related changes both in the inflammatory status and in the gut ecosystem composition, by using 
one of the state-of-the-art molecular techniques for the microbiota characterization, the HITChip 
(Rajilic-Stojanovic et al, 2009). In particular, we decided to expand the usual target populations of 
comparative studies, addressing not only young adults (20-40 years old) and elderly (60-80 years 
old), but also non-hospitalized centenarians. This approach, called the “Centenarians project”, 
aimed at the broadening of our view of the changes which occur in the gut microbiota of adult 
human beings during aging, expanding our vision towards the extreme limits of the human lifespan. 
Gut microbiota composition and diversity, at both qualitative and quantitative levels were analyzed 
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by using the HITChip, and the results were confirmed and deepened by the use of real time-PCR. 
The results of these analyses were correlated with the inflammatory status of each subject, 
evaluated by immunophenotype characterization and quantification of the blood level of several 
pro- and anti-inflammatory cytokines. 
Following the most recent demonstrations of the strong impact of inflammation on the balance 
between symbionts and “pathobionts” in the human gut (Round and Mazmanian, 2009), the 
combined approach presented here allowed us to investigate how perturbation in the gut microbiota 
and inflamm-aging process may affect each other. 
 
In parallel, we overtook the development of our own phylogenetic microarray with a relatively low 
number of targets, aiming the description of the human gut microbiota structure at high taxonomic 
level. The resulting chip was called High Taxonomic level Fingerpring Microbiota Array (HTF-
Microb.Array). 
The gut microbiota exhibits an astonishing degree of individual variability at species level, while 
most of the variations which were correlated to diseases or metabolic disorders consisted in 
dramatic unbalances between groups of bacteria at high taxonomic groups. For instance, it is known 
that obesity is characterized by a higher proportion of Firmicutes and Actinobacteria with respect to 
Bacteroidetes (Turnbaugh et al, 2006; Turnbaugh et al, 2009), whereas IBDs are characterized by a 
reduction of bacterial diversity in the Clostridium cluster IV and XIVa, a decline in Bacteroidetes 
biodiversity, and a correspondent increase in Proteobacteria and Bacillus (Frank et al, 2007).  At the 
light of these observations we decided to focus our attention on larger phylogenetic groups of 
bacteria, instead of species or strains, in order to obtain a tool with the potential to characterize 
dramatic unbalances in the human intestinal microbiota which may be associated with specific 
diseases. 
Due to the low number of probes, the Ligase Detection Reaction (LDR) technology (Castiglioni et 
al, 2004; Hultman et al, 2008) was chosen for the development of the HTF-Microb.Array. This 
technique is based on an enzymatic in vitro reaction and exploits the discriminative properties of the 
DNA ligase. The construction of a LDR-based array requires the design of a pair of two adjacent 
oligonucleotides specific for each target sequence: a probe specific for the variation 
(“Discriminating Probe”, DS) which carries a 5’-fluorescent label, and a second probe, named 
“Common Probe” (CP), starting one base 3'-downstream of the DS that carries a 5’-phosphate 
group and a unique sequence (cZipCode) at its 3’-end. The oligonucleotide probe pairs and a 
thermostable DNA ligase are used in a LDR reaction with previously PCR-amplified DNA 
fragments. This reaction is cycled to increase product yield. The LDR products, obtained only in 
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presence of a perfectly matching template by action of the DNA ligase, are addressed to a precise 
location onto a Universal Array (UA), where a set of artificial sequences, called Zip-codes are 
arranged. These products, carrying both the fluorescent label and the unique cZipCode sequence, 
can be detected by laser scanning and identified according to their location within the array. The 
LDR approach is a highly specific and sensitive assay for detecting single nucleotide variations; 
thus, differences of a single base along the 16S rRNA gene can be employed to distinguish among 
different microbial lineages. 
Here we describe the design procedure, validation and testing of the HTF-Microb.Array, the first 
application of the LDR-array technology to the gut microbial ecosystem characterization. A pilot 
study involving eight healthy young adults demonstrated that the HTF-Microb.Array can be used to 
successfully characterize the human gut microbiota, allowing us to obtain results which are in 
approximative accordance with the most recent characterizations.     
 
Finally, the HTF-Microb.Array analysis and the HITChip approach were compared for validation 
purpose. In particular, the fecal microbiota of five of the centenarians involved in the “Centenarians 
project” was analyzed also with the HTF-Microb.Array, and the results were compared. 
 
The research project presented here resulted in the production of two research articles: “Through 
aging and beyond: gut microbiota and inflammatory status in seniors and centenarians” (Biagi et al, 
submitted to PloS ONE), and “High taxonomic level fingerprint of the human intestinal microbiota 
by Ligase Detection Reaction - Universal Array approach” (Candela et al, submitted to BMC 
Microbiology). 
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3. 
MATERIALS AND METHODS 
 
 
 
3.1 Subjects recruitment and study groups 
 
 3.1.1 Subjects involved in the“Centenarians project” 
Eighty-four subjects belonging to different age groups were enrolled for this study in Emilia 
Romagna, Italy. Group C was composed by 21 centenarians (20 women, 1 men) aged 99 to 104 
years (average 100.5), whose health status was representative of this exceptional population [23]. 
Group E was composed by 22 elderly (11 women, 11 men) aged 63 to 76 years (average 72.7) 
genetically unrelated to the centenarians in group C, and they were offspring of parents who did not 
reach longevity (average parents death age, 59.3). Group Y was composed by 20 young adults (9 
women, 11 men) aged 25 to 40 years (average 31). Group F, offspring of the centenarians belonging 
to group C, composed by 21 elderly people (10 women, 11 men) aged 59 to 78 (average 67.5), was 
also included in the analysis. Subjects of groups E, F, and Y were free living and in good physical 
and cognitive health conditions. Subjects affected by malignant neoplasia and/or in therapy with 
immunosuppressive drugs like cyclosporin, methotrexate, glucorticoids, anticoagulant drugs, and 
who recently (at one month) used antibiotics were excluded from the study. The study protocol was 
approved by the Ethical Committee of Sant’Orsola-Malpighi University Hospital (Bologna, Italy). 
After obtaining informed consent, a standard questionnaire to collect information regarding the 
health status, drugs use, clinical anamnesis, and life style was administrated. Moreover, tests to 
assess cognitive ability (Mini Mental State Examination, MMSE), self sufficiency and autonomy 
(ADL, IADL), physical ability (Handgrip Test and Chair Stand Test), arterial blood pressure 
measurement, and Body Mass Index (BMI) calculation were performed. Peripheral blood and feces 
were collected from each subject. Blood samples were not collected from 3 centenarians and 1 
subject in group F because of refusal or impossibility of the subjects. Principal haemato-
biochemical parameters evaluation and immunophenotypical analyses were performed on freshly 
collected blood samples. The resulting plasma samples were stored at -80°C for less than 3 months, 
and used for the cytokines pattern evaluation. Feces were stored at -80°C and analyses were 
performed within 3 months. 
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     3.1.2 Subjects recruited for the validation of the HTF-Microb.Array on human feces 
Eight healthy Italian subjects, 30 years old in average, were recruited for the validation of the HTF-
Microb.Array n human feces. None of the subjects had dietary restriction, antibiotic therapy or 
functional foods supplementation for at least four weeks prior to sampling. History of 
gastrointestinal disorders at the moment of sampling was considered an exclusion criteria for the 
recruitment. Feces were  stored at -80°C for less than 5 months. The study protocol was approved 
by the Ethical committee of Sant’Orsola-Malpighi Hospital (Bologna, Italy). 
 
3.2 Bacterial strains and culture conditions 
 
 3.2.1 Bacterial DNA used for group specific qPCR standards 
The DNA of the bacterial strains listed in Table 3.1 was used as standard for the group specific 
quantitative real-time PCR (qPCR) in the Centenarians project. 
 
Table 3.1 Bacterial standards used for group specific qPCR  
Target group Standard 
Clostridium leptum group Clostridium leptum ATCC 29065 
Bifidobacterium spp. Bifidobacterium longum ATCC 15707 
Akkermansia spp. Akkermansia muciniphila ATCC BAA-835 
Faecalibacterium prausnitzii Faecalibacterium prausnitzii adhufec218 (Suau et al, 1999) 
Bacteria Escherichia coli ATCC 10798 
Archea Methanobrevibacter smithii ATCC 35061 
 
 
 3.2.2 Bacterial strains used for HTF-Microb.array validation 
For the validation procedure of the HTF-Microb.Array genomic DNA extracted from bacterial 
strains listed in Table 3.2 was used. With the exception of Lactobacillus salivarius SV2, which is 
part of our strain collection, all type strains used for the validation were purchased from DSMZ  and 
ATCC. Salmonella cholerasuis typhimurium and Yersinia enterocolitica were kindly provided by A. 
Essig, Department of Medical Microbiology, University of Ulm, Germany. 
All Bifidobacterium and Lactobacillus strains were grown on De Man-Rogosa-Sharpe (MRS) broth 
(Difco, Lawrence, KS), added of 0.05% of L-cysteine, at 37°C under anaerobic conditions 
(Anaerocult, Merck, Darmstadt, Germany). E. coli was cultivated at 37°C, with shacking, in TY 
broth (Difco). S. cholerasuis typhimurium and Y. enterocolitica were cultivated at 30°C, with 
shacking, in brain-heart infusion (BHI) media (Difco). 
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In the case of strictly anaerobic strains, DNA was extracted from the lyophilized bacterial cells, 
without the cultivation step, (Clostridium leptum, Clostridium viridae, Eubacterium siraeum, 
Megasphaera micrinuciformis, Proteus mirabilis, Ruminococcus albus,  and all Bacillus strains) or 
directly purchased from  ATCC (Campylobacter jejuni, Clostridium acetibutilicum, Clostridium 
difficile, Clostridium perfringens, Prevotella melaninogenica, Veillonella parvula, Ruminococcus 
productus, Bacteroides strains, and Enterococcus strains). 
 
3.3 DNA extraction 
 
 3.3.1 DNA extraction from bacterial cultures 
Bacterial genomic DNA was extracted from bacterial cell cultures using a 10
9
 cells pellet. DNeasy 
Tissue Kit (Qiagen, Duesseldorf, Germany) was used for the extraction, following the manufacturer 
instructions specific for Gram positive bacteria. 
  
 3.3.2 DNA extraction from lyophilized bacterial cells 
Bacterial genomic DNA was extracted by resuspending lyophilized bacterial cells in 1 ml of Lysis 
buffer (500 mM NaCl, 50 mM Tris-HCl pH 8,  50 mM EDTA, 4% SDS). DNA extraction was 
carried out employing the procedure used for the total bacterial DNA extraction from feces. 
 
 3.3.3 DNA extraction from feces 
Total DNA from fecal material was extracted using QIAamp DNA Stool Min Kit (Qiagen) with a 
modified protocol. 250 mg of feces were suspended in 1 ml of Lysis buffer (500 mM NaCl, 50 mM 
Tris-HCl pH 8, 50 mM EDTA, 4 % SDS). Four 3 mm glass beads and 0.5 g of 0.1 mm zirconia 
beads (BioSpec Products, Bartlesville, OK) were added, and the samples were treated in FastPrep 
(MP Biomedicals, Irvine, CA) at 5.5 ms for 3 min. Samples were heated at 95°C for 15 min, then 
centrifuged for 5 min at full speed to pellet stool particles. Supernatants were collected and 260 μl 
of 10 M ammonium acetate were added, followed by incubation in ice for 5 min and centrifugation 
at full speed for 10 min. One volume of isopropanol was added to each supernatant and incubated in 
ice for 30 min. The precipitated nucleic acids were collected by centrifugation for 15 min at full 
speed and washed with ethanol 70%. Pellets were resuspended in 100 μl of TE buffer and treated 
with 2 μl of DNase-free RNase (10 mg/ml) at 37°C for 15 min. Protein removal by Proteinase K 
treatment and DNA purification with QIAamp Mini Spin columns were performed following the kit 
protocol. 
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Table 3.2 Bacterial strains and bacterial genomic DNA used for HTF-Microb.Array validation procedure. 
Species Strain 
Strains from private collections 
Lactobacillus salivarius SV2 
Salmonella cholerasuis typhimurium  
Yersinia enterocolitica  
Strains purchased from DSMZ 
Bacillus cereus DSM21 
Bacillus clausii DSM2515 
Bacillus subtilis DSM704 
Bifidobacterium bifidum DSM20456 
Bifidobacterium breve DSM20091 
Clostridium leptum DSM73 
Clostridium viridae DSM6836 
Eubacterium siraeum DSM15700 
Lactobacillus acidophilus DSM20079 
Lactobacillus casei DSM20011 
Lactobacillus delbrueckii DSM20314 
Lactobacillus gasseri DSM20243 
Lactobacillus pentosus DSM20134 
Lactobacillus plantarum DSM21074 
Lactobacillus ramnosus DSM20021 
Lactobacillus reuteri DSM20016 
Megasphaera micrinuciformis DSM17226 
Proteus mirabilis DSM4479 
Ruminococcus albus DSM20455 
Strains purchased from ATCC 
Bifidobacterium adolescentis ATCC15703 
Bifidobacterium longum ATCC15707 
Escherichia coli ATCC11105 
Bacterial genomic DNA purchased from ATCC 
Bacteroides fragilis ATCC25285 
Bacteroides thetaiotaomicron ATCC29148 
Campylobacter jejuni ATCC33292 
Clostridium acetobutilicum ATCC824 
Clostridium difficile ATCCBAA1382 
Clostridium perfringens ATCC13124 
Enterococcus faecalis ATCC700802 
Enterococcus faecium ATCC51559 
Prevotella melaninogenica ATCC25845 
Ruminococcus productus ATCC23340 
Veilonella parvula ATCC10790 
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3.4 HITChip analysis 
 
 3.4.1 16S rRNA gene amplification 
The total bacterial 16S rRNA genes were amplified from fecal DNA using FastStart Taq DNA 
polymerase, dNTPack PCR Amplification kit (Roche, Mannheim, Germany). T7prom-Bact-27-F 
(5’-TGAATTGTAATACGACTCACTATAGGGGTTTGATCCTGGCTCAG-3’) and Uni-1492-R 
(5’-CGGCTACCTTGTTACGAC-3’) primer set was used for amplification (Lane, 1991). PCR 
reactions were carried out in a final volume of 50 μl and 20 ng of DNA were used as template. 
Initial denaturation step was performed at 95°C for 5 min, followed by 35 cycles of 95°C (30 sec), 
52°C (40 sec) and 72°C (90 sec) and a final extension of 7 min at 72°C. Per DNA sample two 
reactions were performed and pooled before the purification step. PCR products were purified by 
using High Pure PCR Clean up Micro kit (Roche) following the manufacturer instructions. 
 
 3.4.2 In vitro transcription 
T7 RNA transcription was performed by using Riboprobe T7 RNA transcription kit (Promega, 
Madison, WI) on 500 ng of the T7-DNA PCR, according to the manufacturer’s instructions. rATP, 
rCTP, rGTP and a 1:1 mix of rUTP and amino-allyl-rUTP (Ambion, Austin, TX) were used at a 
concentration of 0.5 mM each. Samples were incubated for 15 min at 37˚C, then 1 μl of T7 RNA 
polymerase (Promega) was added to each tube (final volume 20 μl) and the transcription reaction 
was carried out for 90 min. Subsequently, DNAse treatment was performed by using Qiagen RNAse 
free DNAse (Qiagen), according to the manufacturer instructions. RNA purification was performed 
by using RNeasy Mini-elute clean-up kit (Qiagen) and the RNA yield was measured with Nanodrop 
ND-1000. 
 
 3.4.3 Fluorescent labeling 
Amino-allyl-modified nucleotides were coupled with CyDye using Post-Labeling Reactive Dye 
(Amersham Bioscience, Piscataway, NJ ), previously dissolved in DMSO. Two μg of purified RNA 
were used for the labeling reaction, performed in a final volume of 40 μl, in presence of 0.1 M 
sodium bicarbonate buffer (pH 8.7). Samples were incubated for 90 min in the dark, at room 
temperature. The reaction was stopped by adding 15 μl of 4M hydroxylamine and incubating for 15 
min in the dark. Labeled  RNA was purified and measured as described above. 
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 3.4.4 Hybridization and scanning 
HITChip slides were custom synthesized by Agilent Technologies (Wilmington, DE), having a 
8x15K format with 8 arrays per slides. Two different RNA samples, labeled with Cy3 and Cy5, 
respectively, were hybridized on each array. At least 2 hybridizations on different arrays were 
carried out for each sample. 100 ng of each Cy3- and Cy5-labelled RNA were mixed in a final 
volume of 8 μl, then fragmented by adding 1 μl of 10X Fragmentation Reagent (Ambion), and 
incubated for 20 min at 70˚C, according to the manufacturer instruction. The fragmentation reaction 
was stopped by adding 1 μl of Stop Solution. The hybridization mix was prepared by adding to the 
RNA mixture 39 μl of pre-warmed hybridization mix (7.5 μl of 20x SSC, 1.5 μl of ultrapure 10% 
SDS, 30 μl of RNAse-free water). Hybridization was carried out in a rotation oven (Agilent) for 16 
h at 62.5˚C. Slides were washed in 2x SSC, 0.3% SDS at room temperature for 10 min and 0.1x 
SSC, 0.3% SDS at 38˚C for 10 min. SDS was removed by washing the slides in 0.06x SSPE for 5 
min. Microarrays were scanned by using Agilent Microarray Scanner at 2 UV lamp intensities (40 
and 10% of maximum PMT voltage for red, 60 and 20% for green). Intensity values for each spot 
were quantified by using Agilent Feature Extraction software, version 9.5. 
 
 3.4.5 Data analysis 
Data storage, spatial and quantile normalization and probe profile extraction were performed using 
a custom-designed MySQL-based relation database (www.mysql.com) and the R statistical software 
(www.r-project.org), as previously described (Rajilic-Stojanovic et al, 2009). The reproducibility of 
the experiments was assessed by calculating Pearson’s correlation of the natural logarithm of 
spatially normalized signals. Hybridizations which resulted in a Pearson’s correlation coefficient 
(Pearson's r) <0.98 were repeated. For each probe, signal intensity was calculated as the mean value 
of the normalized fluorescence intensities obtained in the 2 replicates. Phylogenetic profile of each 
subject was obtained by plotting probes hybridization signals grouped by specificity of probes. 
Hierarchical clustering of HITChip profiles was carried out using Pearson’s correlation to calculate 
the distance among samples and Ward’s minimum variance as agglomeration method. 
For quantification purpose, the analysis was focused on the 129 of “level 2” phylogenetic groups, 
which corresponds to subsets of phylotypes with 90% or more 16S rRNA sequence similarity. The 
average signal intensity of all probes which are specific for one phylogenetic group was used as 
quantitative measure of that group in the sample. The cut-off values for positive responding probes 
were calculated as described by Rajilic-Stojanovic et al (2009). Statistics were performed on log-
transformed data using the R statistical software and the Canoco package for Windows (Leps and 
Smilauer, 2003). To evaluate the significance of the difference between datasets, P value was 
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calculated by Student t-test for normally distributed data, or Wilcoxon rank sum test for not-
normally distributed data. P value <0.05 was considered as threshold for statistical significance. 
Simpson’s reciprocal index of diversity (Simpson, 1949), was used to express the diversity of 
microbial communities, calculated using the equation λ = 1/Σ Pi2, where Pi is the proportion of the 
i
th
 taxon. The proportion of each taxon was calculated as the proportion of each probe signal 
compared to the total signal. Simpson’s reciprocal index of diversity takes into account both the 
number of taxon present in a sample and their abundance in the community. A higher value of 
Simpson index corresponds to a more diverse community. 
 
3.5 Real time PCR analysis 
 
Quantitative real time PCR (qPCR) analysis was carried out in a Applied Biosystems 7300 Fast 
Real-Time PCR System in a 96-well format and using SYBR Green chemistry (Power SYBR Green 
PCR Master Mix, Applied Biosystems, Foster City, CA) and 0.2 µM of each primer. The total 
volume of qPCR reaction was 25 µl, employing 1 µl of DNA sample or standard as a template. The 
forward (F) and reverse (R) primers are listed in Table 3.3.  The previously described thermocycling 
conditions were used (Kaufmann et al, 1997; Kullen et al, 2000; Marteau et al, 2001; Baker et al, 
2003; Matsuki et al, 2004; Rinttila et al, 2004; Collado et al, 2007). Samples were assayed in 
duplicate in at least 2 independent runs and the results were analyzed using Applied Biosystems 
7300 Fast Real-Time PCR System SDS Software (version 1.4.0). Melting curve analysis was 
performed after the PCR to confirm specificity of amplification. The amount of 16S copies of 
specific bacterial genera or groups in the fecal samples was determined by comparing the Ct 
(threshold cycle) values of samples to those of the standard curves. 
Standards were prepared by amplifying the 16S rDNA from a representative species from each 
bacterial group targeted by qPCR. The amplified fragments were subsequently purified by the using 
the QIAquick PCR purification kit (Qiagen), quantified by using the NanoDrop ND-1000 and 
diluted appropriately for use as standards. Statistical analysis of qPCR data was carried out with 
log-transformed data. Non-detected values were imputed with the half of the theoretical detection 
limit. Nonparametric tests were used since data were not normally distributed. Kruskall-Wallis test 
was used to determine the statistical differences among the age groups. Mann-Whitney U-test was 
used for pair-wise comparisons. P value < 0.05 was considered as a threshold for statistical 
significance. 
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Table 3.3 Group specific primer set used in qPCR 
Specificity Primer set Ref. 
Bacteria 
F 5’-AGAGTTTGATCCTGGCTCAG-3’ 
Kullen et al, 2000 
R 5’-GGCTGCTGGCACGTAGTTAG-3’ 
Clostridium leptum group 
F 5'-GCACAAGCAGTGGAGT-3' 
Matsuki et al, 2004 
R 5´-CTTCCTCCGTTTTGTCAA-3´ 
Bifidobacterium genus 
F 5'-GATTCTGGCTCAGGATGAACGC-3' Kaufmann et al, 1997 
Marteau et al, 2001 R 5'-CTGATAGGACGCGACCCCAT-3' 
Akkermansia muciniphila 
F 5'-CAGCACGTGAAGGTGGGGAC-3' 
Collado et al, 2007 
R 5'-CCTTGCGGTTGGCTTCAGAT-3' 
Faecalibacterium prausnitzii 
F 5'-CCCTTCAGTGCCGCAGT-3' 
Rinttila et al, 2004 
R 5´-GTCGCAGGATGTCAAGAC-3´ 
Methanobrevibacter smithii 
F 5'-CCGACGGTGAGRGRYGAA-3' 
Baker et al, 2003 
R 5-YCCGGCGTTGAMTCCAATT-3' 
 
 
3.6 Immunological characterization 
 
 3.6.1 Immunophenotyping 
The identification of the major lymphocyte subsets (B lymphocytes, T lymphocytes, virgin T 
lymphocytes, memory T lymphocytes and NK cells), some of which considered important for the 
immunological risk phenotype, was performed  using the following combination of monoclonal 
antibodies: CD5/CD19 to identify B and autoreactive B lymphocytes, CD3/CD4/CD8 to identify T 
lymphocytes subsets, CD28/CD95/CD4 and CD28/CD95/CD8 to identify effector T helper and 
cytotoxic lymphocytes, CD45RA/CD4/CCR7 and CD45RA/CD4/CCR7 to identify naive, central 
memory, effector memory and terminal effector T helper and cytotoxic lymphocytes and 
CD4/CD25/CD8 to identify activated T lymphocytes. The phenotypical analysis of peripheral blood 
lymphocytes on whole blood samples lysis was performed as previously described (Cossarizza et 
al, 1990). To quantify the main lymphocyte sub-populations, a cytometric approach with 
fluorochrome-labelled monoclonal antibodies (mAbs) directly conjugated to fluorescent molecules 
(fluorescein isothiocyanate, FITC; phycoerythrin, PE; phycoerythrin-cy-crhome, PE-Cy7) staining 
was used. mAbs, including the appropriate isotype controls, were purchased from BD Biosciences 
Pharmingen (San Diego, CA). Phenotypic analyses of cytotoxic and helper subsets were performed 
placing an electronic gate on CD8+ and CD4+ cells and evaluating the expression of CD45RA 
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versus CCR7, i.e. naïve (CD45RA+CCR7+), central memory (CD45RA-CCR7+), effector memory 
(CD45RA-CCR7-), and terminal effector (CD45RA-CCR7+). Similarly, the expression of CD25 
was analyzed on CD8+ and CD4+ gate. Data were acquired using a FACScalibur (BD Biosciences) 
flow cytometer and analyzed with FlowJo (Tree Star Inc., Ashland, OR) software. A minimum of 
30,000 cells per sample was acquired. 
 
 3.6.2 Plasmatic cytokines evaluation 
Levels of IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IFN-γ, and TNF-
samples were measured in duplicate by multiplex sandwich ELISA technology (Human Cytokine 
Array 1, SearchLight, Aushon Biosystems, Billerica, MA) according to the manufacturer’s 
instructions. The concentration of each analyte in the array was detected by biotin-streptavidin 
reaction and quantified by a SearchLight CCD Imaging System. The lowest detectable 
concentrations were the following: 0.1 pg/ml for IL-1α, 0.1 pg/ml for IL-1β, 0.4 pg/ml for IL-2, 0.2 
pg/ml for IL-6, 0.4 pg/ml for IL-8, 0.2 pg/ml for IL-10, 0.3 pg/ml for IL-12p70, 0.1 pg/ml for IFN-
γ, 0.6 pg/ml for TNF-α. 
standardized technique employing a robotic liquid handling system with 16 channels (Microlab® 
STAR, Hamilton Robotics, Reno, NV). Plasmatic TGF-β1 concentration was determined in 
duplicate by ELISA using a commercial kit (DRG Instruments GmbH, Marburg, Germany) 
according to the manufacturer’s instructions. The analytical sensitivity was 1.2 pg/ml. The 
interassay coefficient of variation was 7.5%. Concentration of TGF-β1 was detected and quantified 
by a Synergy HT Multi-Detection Microplate Reader (Bio-Tek® Instruments, Winooski, VT). 
 
 3.6.3 Inflammation score 
Aiming the evaluation of the inflammatory status of each subject, an inflammation score was 
calculated as inspired by previous studies (Duncan et al, 2003; Recasens et al, 2005). The score was 
composed of 8 markers: white blood cell count, C reactive protein, number of central memory 
helper and cytotoxic T lymphocytes (CD45RA-CCR7+), number of effector helper and cytotoxic T 
lymphocytes (CD28-), IL-6 and IL-8 plasmatic levels. The inflammation score ranging from 0 to 8, 
was calculated by adding 1 unit for each value greater than the median of the study samples for each 
inflammatory marker. Subjects with at least 5 markers greater than the median, with an 
inflammation score between 5 and 8, were considered  highly inflamed while IS between 0 and 4 
was considered as indication of low inflammatory status.   
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3.7 HTF-Microb.Array design 
 
 3.7.1 Target selection and consensus extraction 
A database of 16S rRNA sequences was created by integration of the 16S rRNA database of the 
ARB Project (release February, 2005) (Ludwig et al, 2004), with the database of the Ribosomal 
Database Project (RDP; release September, 2007) (Cole et al, 2007; Wang et al, 2007). A 
phylogenetic tree was obtained in the ARB software, by using the neighbour-joining algorithm for 
the sequence alignment. The tree was used for the rational selection of phylogenetic groups of 
bacteria belonging to the human intestinal microbiota which correspond to nodes of the 
phylogenetic tree (Appendix 1). Group specific consensus sequences were extracted, with a cut-off 
of 75% for base calling. Nucleotides which occurred at lower frequencies were replaced by the 
appropriate IUPAC ambiguity code. 
 
 3.7.2 Probe design 
Multiple alignment step of the selected sequences was performed in ClustalW (Chenna et al, 2003). 
Since the taxonomic classification of the 30 groups selected for the probe design varied from 
species to phylum level, careful grouping of the sequences was performed for the multiple 
alignment step: (a) for higher level probes, only family/phylum consensus sequences were used as a 
negative set for probe design; (b) for genus/species level probes, only sequences belonging to other 
families/phyla were selected. All the LDR probe pairs were designed in collaboration with the 
Institute for Biomedical Technologies, Milan, Italy, using the tool ORMA (Severgnini et al, 2009). 
Both DS and CP were required to be between 25 and 60 bases pair, with a Tm of 68±1°C, and with 
maximum 4 degenerated bases. In-silico check versus a publicly available database (i.e. RDP) was 
then performed for assessing probe pair specificity. 
 
3.8 LDR/Universal Array approach 
 
 3.8.1 Universal Array construction 
The construction of the Universal Array and the Ligase Detection Reactions (LDR) were performed 
at the Institute for Biomedical Technologies, Milan, Italy. All the oligonucleotide probe pairs were 
synthesized by Thermo Electron (Ulm, Germany). 
Phenylen-diisothiocyanate (PDITC) activated chitosan glass slides were used as surfaces for the 
preparation of Universal Arrays (Gerry et al, 1999), comprising a total of 49 Zip-codes. Spotting 
was performed by using a contact-dispensing system (MicroGrid II Compact, BioRobotics, 
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Huntingdon, UK). The printed slides were processed according to the manifacturer's protocols. 
Eight arrays per slide were generated. Hybridization controls (cZip 66 oligonucleotide, 
complementary to zip 66, 5’-Cy3-GTTACCGCTGGTGCTGCCGCCGGTA-3’) were used to locate 
the submatrixes during the scanning. The entire experimental procedure for both the chemical 
treatment and the spotting is described in detail in Consolandi et al (2006). 
 
 3.8.2 16S rRNA gene amplification 
The 16S rRNA gene was amplified using universal forward primer 16S27F (5’-
AGAGTTTGATCMTGGCTCAG-3’) (Edwards et al, 1989) and reverse primer R1492 (5’-
TACGGYTACCTTGTTACGACTT-3’) (Weissburg et al, 1991), following the protocol described in 
Castiglioni et al (2004), except for the use of 50 ng of starting DNA and 0.5U of DyNAzyme II 
DNA polymerase (Finnzymes, Espoo, Finland). Briefly, PCR reactions were carried out in a final 
volume of 25 μl and 50 ng of DNA were used as template. Initial denaturation step was performed 
at 95°C for 10 min, followed by 30 cycles of 94°C (45 sec), 60°C (45 sec) and 72°C (90 sec) and a 
final extension of 10 min at 72°C. PCR products were purified by using High Pure PCR Clean up 
Micro kit (Roche) following the manufacturer instructions. PCR products were purified by using a 
Wizard SV gel and PCR clean-up System purification kit (Promega), according to the 
manufacturer’s instructions, eluted in 20 μl of sterile water, and quantified with the DNA 7500 
LabChip Assay kit and BioAnalyzer 2100 (Agilent Technologies). 
 
 3.8.3 LDR and hybridization 
A schematic representation of the LDR/Universal Array approach is presented in Fig. 3.1. 
LDR and hybridization of the products on the Universal Arrays were performed according to the 
protocol described by Castiglioni et al (2004), except for the probe annealing temperature, which 
was set at 60 °C. The LDRs were carried out in a final volume of 20 μl with different quantities of 
purified PCR products. All LDRs for specificity tests were performed on 50 fmol of initial PCR 
product, for having no issues related to target. Sensitivity tests were performed with decreasing 
PCR product concentration from 75 to 0.7 fmol. Relative abundance tests were performed on 1 fmol 
E. coli PCR amplicon, mixed with human genomic DNA, at decreasing concentrations, from 4%, 
down to 0.02%. LDR experiments on the eight faecal samples were performed on 50 fmol of PCR 
product. 4U of Pfu DNA ligase (Stratagene, La Jolla, CA) were used for each reaction. 
Hybridizations were performed on a final volume of 65 μl, containing the 20 μl of the LDR, 16 μl 
of 20X SSC buffer, 0.1 mg of Salmon sperm DNA. After heating at 94°C  for 2 min and chilling on 
ice, the hybridization mix was applied to the slide, using Press-to-Seal silicon isolators (Schleicher 
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& Schuell BioScience, Dassel, Germany) to separate the 8 arrays. Hybridization was carried out in 
the dark at 60°C for 1 h. Then the slide was washed in pre-warmed 1X SSC, 0.1% SDS for 15 min, 
and dried by centrifugation. 
 
 3.8.4 Data analysis 
All arrays were scanned with ScanArray 5000 scanner (Perkin Elmer Life Sciences, Boston, MA), 
at 10 μm resolution. In the experiments, the fluorescent images were obtained with different 
acquisition parameters on both laser power and photo-multiplier gain, in order to avoid saturation. 
Fluorescence Intensities (IF) were quantified by ScanArray Express 3.0 software, using the 
“Adaptive circle” option, letting diameters vary from 60 to 300 μm. No normalization procedures 
on the IFs have been performed. To assess whether a probe pair was significantly above the 
background (i.e. was “present” or not), we performed a one-sided t-test. The null distribution was 
set as the population of “Blank” spots (e.g. with no oligonucleotide spotted). For each zip-code, we 
considered the population of the IFs of all the replicates (n=4) and tested it for being significantly 
above the null-distribution. In case one replicate in the test population was below 2.5 times the 
distribution mean, this was considered an outlier and was discarded from the analyses. Data 
analyses were performed using the software Matlab, in collaboration with the Institute for 
Biomedical Technologies, Milan, Italy. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. (Following page) Main features of LDR method coupled with a universal microarray. After 
hybridization of a discriminating probe and a common probe to the target sequence (16S rRNA gene), 
ligation occurs only if there is perfect complementarity between the two probes and the template (A). The 
reaction is thermally cycled, generating single-stranded DNA fragments bearing a 5' Cy3 fluorescent moiety 
and a 3' czip code sequence. The cycling allows more common probe (and the corresponding czip code) to 
ligate to the discriminating probe, given a fixed amount of PCR target. (B) The LDR product is hybridized to 
a universal microarray, where unique zip code sequences have been spotted. (Castiglioni et al, 2006) 
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4. 
RESULTS 
 
4.1 The “Centenarians project”: characterization of the gut microbiota 
 
 4.1.1 HITChip profiling of centenarians, elderly and young adults 
The fecal microbiota of centenarians (group C), elderly (group E) and young adults (group Y) was 
characterized using the recently developed diversity microarray HITChip (Rajilic-Stojanovic et al, 
2009). Hybridization was performed in at least 2 replicates for each sample, and reproducibility was 
tested by calculating Pearson’s correlation coefficient (Pearson’s r) and Relative Standard Deviation 
(RSD). For each subject a phylogenetic fingerprint of the intestinal microbiota was obtained. 
Pearson’s r ranged between 0.982 and 0.999, with a mean value of 0.993, showing that the HITChip 
profiles were highly reproducible. RSD ranged between 1.8% and 13.2%, with a mean value of 
5.1%. 
Hierarchical clustering with heat map of the level 2 average hybridization signals (Fig. 4.1) showed 
that centenarians grouped together, whereas no separation of subjects belonging to groups E and Y 
was observed. The proportion of centenarians in cluster 3 (67%) is significantly higher than in the 
other clusters (χ2 test, P value = 0.001). Clusters 1 and 2 contain similar proportions of each age 
groups (18% C, 44% E, 39% Y, for cluster 1; 22% C, 38% E, 38% Y, for cluster 2). According to 
the heat map result, the gut microbiota of subjects in cluster 3 is characterized by higher amounts of 
Proteobacteria and Bacilli, and decreased amounts of Clostridium cluster XIVa bacteria. Finally, 
Bacteroidetes showed remarkably lower intensities in cluster 1, which is composed by mixed 
subjects, highlighting that the decrease in Bacteroidetes amount in the gut microbiota does not seem 
to be related to the aging. 
Multivariate analysis was carried out using the age groups C, E, and Y as nominal environmental 
variables, and the log-transformed average hybridization signal for the 129 level 2 phylogenetic 
groups as “species” variables. Ordination plot in Fig. 4.2 shows the redundancy analysis (RDA), 
which focuses on the major carriers, accounting for more than 10% of the difference among the 
groups of samples. The differences shown in RDA are highly significant (P value = 0.002) as 
assessed by Monte Carlo Permutation Procedure (MCPP). 6.1% of the total variation in the dataset 
could be related to the environmental variable. Most of this variation (5.2%) is plotted on the first 
axis that separates the centroid of group C from the other two groups E and Y. E and Y centroids are 
plotted on a line along the second axis, which shows only 0.9% of variability. The analysis 
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indicated that the differences in the microbiota fingerprint between centenarians and all the other 
subjects are greater than the differences between elderly and young adults. Samples of groups C and 
Y form almost separate clusters in RDA, whereas the group E cluster overlap with both of them. 
Confirming the heatmap results, RDA showed that the fecal microbiota of centenarians is enriched 
in many facultative anaerobes, mostly belonging to the Proteobacteria (Escherichia coli et rel., 
Haemophilus, Klebsiella pneumoniae et rel., Leminorella, Proteus et rel., Pseudomonas, Serratia, 
Vibrio, and Yersinia et rel.), and Bacilli (Bacillus, Staphylococcus). On the other side of the plot, 
higher amounts of many bacterial groups belonging to the Clostridium cluster XIVa seemed to 
characterize the fecal microbiota of samples of groups E and Y. Interestingly, the arrows 
corresponding to the phylogroups Faecalibacterium prausnitzii et rel. and Clostridium leptum et 
rel., both belonging to the Clostridium cluster IV, pointed in opposite directions, indicating that F. 
prausnitzii group decreased in centenarians whereas C. leptum group increased. 
Gender and BMI were also used as environmental variables in multivariate analyses, but they did 
not show any relation with the gut microbiota composition of the subjects (data not shown). 
The diversity of the microbial communities in the different age groups was assessed. The diversity 
discovered by the HITChip was expressed as Simpson reciprocal index of diversity. Simpson 
indices obtained for group C (127.0 ± 54.2) were significantly lower than those obtained for E 
(149.4 ± 40.5, P = 0.02) and Y (162.8 ± 35.1, P = 0.002), indicating that the microbiota of 
centenarians is significantly less diverse than that of elderly or adults. On the contrary, the 
difference between Simpson indices of E and Y was not statistically significant. 
Correlation matrices were obtained for each groups of samples in order to investigate the inter-
individual variability in the different age groups (Fig. 4.3). Pearson correlation coefficients were 
calculated comparing the hybridization profile of each subject with all the subjects of the same 
group. Mean Pearson correlation coefficients of 0.36, 0.47 and 0.47 were obtained for groups C, E, 
and Y, respectively. This analysis pointed out that centenarians are significantly less correlated to 
each other for their gut microbiota composition, if compared to subjects belonging to groups E (P < 
0.0001) and Y (P < 0.0001). 
 
Fig. 4.1 (following page) Hierarchical clustering, with heat map, of the gut microbiota profiles of 
centenarians, elderly and young adults. Subjects belonging to the groups C, E, and Y are indicated 
by black circles, grey squares and white squares, respectively. Darkness of the spot corresponds to 
the bacterial abundance in the sample. Pearson correlation of level 2 phylogeny and Ward’s 
clustering method were used. Level 2 phylogenetic groups members of the Proteobacteria (P), 
Bacilli (B), Clostridium cluster IV (C.IV) and XIVa (C.XIVa) are indicated. The two phylogroups 
members of the Clostridium cluster IV located within the Clostridium cluster XIVa cluster (bottom) 
are Faecalibacterium prausnitzii et rel. and Papillibacter cinnamovorans et rel. 
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Fig. 4.2. Triplot of the RDA of the microbiota composition of centenarians, elderly and young adults. 
Subjects belonging to group C, E, and Y are indicated by green circles, blue squares and yellow diamonds, 
respectively. Constrained explanatory variables (C, E, and Y) are indicated by red triangles. Responding 
bacterial subgroups that explained more than 10% of the variability of the samples are indicated by black 
arrows. First and second ordination axes are plotted, showing 5.2% and 0.9% of the variability in the dataset, 
respectively. Log transformed data were used for the analysis. Bottom-left, P value obtained by MCPP is 
reported. Abbreviations: C., Clostridium; E., Eubacterium; F., Faecalibacterium; R., Ruminococcus; K., 
Klebsiella. 
 
 
 
 
 
 
Fig 4.3. Boxplot of the Simpson indices obtained for 
the gut  microbiota profiles of subjects in groups C 
(green), E (blue), and Y (orange).The box for each 
group represents the interquartile range (25–75th 
percentile) and the line within this box is the median 
value. Bottom and top bars indicate the 10th and 90th 
percentiles, respectively. Outlier values are indicated 
(circles). Median values are also reported for each 
bacterial group at the bottom of the plots. 
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Fig. 4.4. Correlation matrices obtained for groups of subjects C, E and Y. Pearson correlation coefficient 
obtained when the gut microbiota profile of each subject was compared to all the others in the same group 
are represented in a scale from red (Pearson's r = 1, high similarity) to lime green (Pearson's r = -1, low 
similarity). 
 
 
 
 4.1.2  Quantitative differences between the gut microbiota of centenarians, elderly and  
  young adults 
The relative contributions of the major phyla (level 1 phylogenetic groups, corresponding to the 
phylum/order level) in the fecal microbiota of the subjects in groups C, E and Y are plotted in Fig. 
4.5. Bacteroidetes and Firmicutes contributed to the fecal microbiota for the 93% in the case of 
centenarians, and 95% in both groups E and Y. Bacteroidetes contributed for 20, 16, and 19% to the 
total microbiota of subjects belonging to groups C, E and Y, respectively. The 
Firmicutes/Bacteroidetes ratios obtained for groups C, E and Y were 3.6, 5.1, and 3.9, respectively. 
To evaluate the significance of this difference, the sum of the hybridization signals of the probes 
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which referred to the Bacteroidetes and the Firmicutes was calculated for each subject. The 
differences among groups of samples, in both the Bacteroidetes proportions and the 
Firmicutes/Bacteroidetes ratios, were not statistically significant (P = 0.73, and P = 0.55, 
respectively). 
Clostridium cluster IV contributed for the 22% to the microbiota of all age groups. qPCR for C. 
leptum group, which is comparable to Clostridium cluster IV, showed no significant difference 
between centenarians and other age groups (Table 4.1), confirming the HITChip result. Conversely, 
qPCR showed that E have significantly more C. leptum group bacteria when compared to Y (P = 
0.05), although no statistical difference in HITChip signals was observed. The relative contribution 
of Clostridium cluster XIVa is clearly lower in centenarians (34%) than in the other groups (49%, 
group E; 44% group Y). By comparing the sum of the hybridization signals of the probes which 
referred to the Clostridium cluster XIVa in the C and E groups, and in the C and Y groups, P values 
of 0.001 and 0.02 were obtained, respectively. The proportion of Bacilli is significantly higher in 
centenarians (12%), if compared to groups E (5%, P = 0.05) and Y (5%, P = 0.03). Centenarians 
also tended to have a higher proportion of Proteobacteria (2.6%) with respect to E (1.2%, P = 0.06) 
or Y (1.2%, P = 0.07). 
 
 
Table 4.1 Quantitative PCR results for bacterial groups, expressed as average amount of 16S rRNA copies 
per µg of fecal DNA. Ratios of bacterial 16S DNA counts between groups C, E and Y are indicated. P values 
<0.05 are reported. 
Bacterial group 
Average values (16S copies/ug 
fecal DNA) 
Ratio P values 
C E Y C/E C/Y E/Y CvsE CvsY EvsY 
Clostridium leptum 
group 
1.99E+07 3.02E+07 1.60E+07 0.7 1.3 1.9 / / 0.05 
Faecalibacterium 
prausnitzii 
2.01E+07 6.99E+07 3.80E+07 0.3 0.5 1.8 0.02 / / 
Bifidobacterium spp. 6.57E+08 6.87E+08 9.50E+08 1 0.7 0.7 / 0.02 / 
Akkermansia 2.75E+06 1.45E+06 1.22E+06 1.9 2.2 1.2 / / 0.01 
Archaea 1.98E+06 1.48E+06 4.58E+05 1.3 4.3 3.2 / / / 
Universal (total 
bacteria) 
1.78E+09 1.39E+09 1.38E+09 1.3 1.3 1 / / / 
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In order to have a more detailed view of the age-related 
changes in the core gut microbiota composition, 
analysis was focused on the level 2 phylogenetic 
bacterial groups (genus-like level) having 100% of 
prevalence (defined as percentage of  positive samples 
in each study group) in all the age groups. The core 
microbiota was constituted principally of  Bacteroidetes 
and Firmicutes, mostly Clostridium clusters XIVa and 
IV. Bacterial groups with significantly different 
abundance in groups C, E and Y, as well as several 
bacterial groups showing a tendency (P values = 0.05-
0.08) of increased or decreased abundance in the 
different age groups, are listed in Table 4.2. In 
accordance with the RDA result (Fig. 4.2), the vast 
majority of the significant differences in bacterial 
groups were found when group C was compared to E 
and Y. Ratio of the average hybridization signals 
obtained for groups C and E, and C and Y, is reported to 
highlight the increase or decrease of each level 2 
phylogenetic group at the different stage of life. Most of 
the bacteria that significantly decreased in group C with 
respect to both E and Y (highlighted in grey in Table 2) 
belonged to Clostridium cluster XIVa. In Clostridium 
cluster IV, Papillibacter cinnamovorans et rel., and F. 
prausnitzii et rel. showed a significant decrease in 
centenarians, while C. leptum et rel., Sporobacter 
termiditis et rel., Anaerotruncus colihominis et rel., 
Clostridium orbiscindens et rel. showed a significant 
increase. The decrease of F. prausnitzii in centenarians 
with respect to the other two age groups was confirmed 
by qPCR analysis (Table 4.1). 
 
 
Fig 4.5. Relative contribution of the 
level 1 phylogroups to the fecal mi-
crobiota of subjects in groups C, E, 
and Y. In the legend, phylogroups 
which contribute for at least 0.5% to 
one of the profiles are indicated. 
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Considering that the relative proportion of Clostridium cluster IV in the total microbiota remained 
unaffected by the age of the subjects (Fig. 4.5, Table 4.1), the analysis of level 2 phylogenetic 
groups suggests a rearrangement in the composition of this bacterial cluster, in terms of genera or 
species, in centenarians. 
 
Confirming the RDA results (Fig. 4.2), the average amount of all the bacteria listed above did not 
significantly differ between E and Y. Differences between E and Y were found only for the groups 
Acquabacterium (P = 0.05), Collinsella et rel. (P = 0.04), and Dialister et rel. (P = 0.02). These 
groups, belonging to Proteobacteria, Actinobacteria and Clostridium cluster IX, respectively, are not 
highly represented in the human gut. Moreover, for all the bacterial groups which showed 
significant differences between centenarians and all the other subjects, the HITChip signal ratios 
C/E and C/Y were often very similar (Table 4.2), suggesting that the changes in the composition of 
the gut microbiota are not linearly correlated with the age. 
 
In addition to the qPCR analyses of Clostridium cluster IV and F. prausnitzii, performed to confirm 
the HITChip results, we quantified bifidobacteria and Akkermansia, which in previous studies had 
shown to decrease in the old age (Table 4.1). qPCR revealed that the amount of total bifidobacteria 
was significantly lower in C when compared to Y (P = 0.023). However, no statistical difference 
was detected in the Bifidobacterium signals in the HITChip. This discrepancy is likely due to the 
lower quantitative sensitivity of the HITChip, with respect to the qPCR, which detected a difference 
of only 0.3 log unit between groups C and Y. The amounts of Akkermansia spp. were comparable 
between centenarians and other age groups, both in qPCR and HITChip analysis. However, by 
qPCR, subjects in group Y were observed to harbour significantly less Akkermansia than group E, 
both in means of prevalence and amount of 16S copies. 
We also quantified by qPCR the archea, which are not targeted by the HITChip. The amount of 
archaeal DNA did not show any significant difference between centenarians and the other age 
groups (Table 4.1). Interestingly, centenarians tended to harbour archaea more frequently than the 
elderly or young adults (prevalence 65%, 36% and 45%, respectively), although the difference was 
not significant. 
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Table 4.2. Bacterial groups that were found to differ significantly between centenarians (C), elderly (K) 
and young adults (Y). Ratio calculated between the average relative abundance of each phylogroup in the 
HITChip in C and K, and C and Y are reported. Shadowed, are the bacterial groups which showed C/K and 
C/Y ratio <1, indicating a decrease in the subjects of group C. P values are reported for each difference. 
Several bacterial groups with P values ranging from 0.05 to 0.08 are also listed. 
 
Phylum/order 
 
Level 2 phylogenetic group 
Ratio P value 
C/K C/Y C vs K C vs Y 
Clostridium cluster XV Eubacterium limosum et rel. 16.2 14.5 < 0.001 0.01 
Proteobacteria 
Klebsiella pneumoniae et rel. 5.3 6.7 0.002 < 0.001 
Vibrio 5.4 5.4 < 0.0001 < 0.0001 
Enterobacter aerogenes et rel. 1.9 2.1 0.03 0.04 
Actinobacteria Eggerthella lenta et rel. 1.8 2.7 0.02 < 0.001 
Bacilli Bacillus 1.4 2 0.01 0.04 
Clostridium cluster IV 
Clostridium leptum et rel. 1.8 1.8 0.006 0.005 
Sporobacter termiditis et rel. 1.5 1.6 0.05 0.04 
Anaerotruncus colihominis et rel. 1.4 1.5 0.08 0.01 
Clostridium orbiscindens et rel. 1.4 1.3 0.03 0.08 
Faecalibacterium prausnitzii et 
rel. 
0.5 0.5 0.01 0.006 
Papillibacter cinnamovorans et 
rel. 
0.7 0.7 0.06 0.04 
Clostridium cluster XIVa 
Clostridium colinim et rel. 0.4 0.6 0.06 0.05 
Clostridium sphenoides et rel. 0.5 0.6 < 0.001 0.003 
Eubacterium hallii et rel. 0.7 0.5 0.03 0.004 
Eubacterium rectale et rel. 0.5 0.5 0.001 0.004 
Eubacterium ventriosum et rel 0.4 0.4 < 0.001 < 0.001 
Lachnobacillus bovis et rel. 0.6 0.8 0.007 0.03 
Outgrouping Clostridium cluster 
XIVa 
0.7 0.6 0.02 0.01 
Roseburia intestinalis et rel. 0.5 0.5 0.006 0.03 
Ruminococcus lactaris et rel. 0.6 0.7 0.002 0.01 
Ruminococcus obeum et rel. 0.6 0.6 0.003 0.01 
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 4.1.3 The effect of genetic: microbiota comparison between centenarians and their offspring 
In order to assess if the microbiota of centenarians can be related to that of their offspring, the 
HITChip analysis was performed on samples from group F, composed of 21 offspring subjects of 
centenarians. The average age in group F was 67.5 years. The HITChip profile of each centenarian 
was compared to that of his/her offspring, and to the profile of randomly selected subjects 
belonging to the group E, and Pearson’s correlation indices were calculated. A mean Pearson’s r of 
0.42 ± 0.18 for the C-F pairs and 0.44 ± 0.20 for the C-E pairs were obtained. The result 
demonstrates that the gut microbiota composition of parents and offspring shows no significant 
similarity at the old age (P = 0.79). 
The average Simpson diversity indices obtained for group F was 151.7 ± 49.3. The microbiota of 
elderly belongings to groups E and F did not differ in diversity as assessed by Simpson index (P = 
0.87). Also the proportions of the level 1 phylogenetic groups in groups E and F were comparable 
(data not shown). 
RDA analysis showed that samples of the F and E groups were mixed and the centroids were close 
to each other, whereas the centroid of group C was plotted distant from both of them (Fig. 4.6). No 
significant differences in the overall microbiota composition were found between groups F and E 
(MCPP, P = 0.39). The statistically significant differences in bacterial groups between C and E 
(Table 4.2) were also found to differ significantly between C and F (data not shown). In general, the 
microbiota of elderly people in group F seemed more similar to the microbiota of subjects in the 
age-matched group E, than to that of their centenarian parents. 
Phylotypes belonging to the major bacterial phyla of the human gut microbiota, such as Clostridium 
cluster IV and XIVa and Bacteroidetes, were present in all study subjects. On the other hand, some 
bacterial groups which are less represented in the human gut ecosystem, such as Fusobacteria and 
Proteobacteria, showed higher prevalence (the percentage of positive samples in each study groups) 
in centenarians and their offspring than in E or Y groups (Table 4.3). The most noticeable 
differences in the prevalence concerned Campylobacter, Helicobacter and Fusobacterium. This 
trend is mainly limited to opportunistic or potentially pathogenic bacterial groups, and it is likely to 
reflect the microbial exposure in the shared living environment and/or the close contacts between 
family members, since most of the subjects in group F (13 out of 21, defined as group FC) lived 
with their centenarian parent. Several of the phylogroups listed in Table 4.3, Asteroplasma et rel., 
Peptostreptococcus micros et rel., Fusobacterium, Alcaligenes faecalis et rel., Campylobacter, 
Desulfovibrio et rel., Helicobacter, Leminorella, Moraxellaceae, Proteus et rel., Brachyspira, 
showed higher prevalence values in group FC than in group FN, a subset of group F including the 
offspring subjects who did not live with their parents. 
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Table 4.3. Bacterial groups which showed differences in terms of prevalence between groups C, F, K, and 
Y. Prevalence values of subsets of group F, FC (offspring who lived with their centenarian parents) and FN 
(offspring who do not live with their centenarian parents). 
 
Phylum/order 
 
Level 2 phylogenetic group 
Prevalence (%) 
C F (FC, FN) K Y 
Actinobacteria 
Corynebacterium 90 90 (83, 100) 50 40 
Micrococcaceae 90 76 (83, 67) 59 35 
Asteroplasma Asteroplasma et rel. 48 38 (42, 33) 32 20 
Bacilli Staphylococcus 100 100 (100, 100) 91 85 
Clostridium cluster XI 
Peptostreptococcus anaerobius et 
rel. 
76 100 (100, 100) 59 55 
Peptostreptococcus micros et rel. 52 52 (67, 33) 18 15 
Fusobacteria Fusobacterium 28 43 (50, 33) 5 5 
Proteobacteria 
Alcaligenes faecalis et rel. 71 81 (92, 67) 50 35 
Bilophila et rel. 90 86 (83, 89) 68 70 
Campylobacter 29 33 (50, 11) 5 5 
Desulfovibrio et rel. 90 90 (100, 78) 77 50 
Escherichia coli et rel. 95 81 (75, 89) 77 70 
Haemophilus 90 76 (75, 79) 68 55 
Helicobacter 33 33 (50, 11) 5 5 
Leminorella 95 76 (83, 67) 64 65 
Moraxellaceae 48 38 (58, 11) 18 10 
Oceanospirillum 57 76 (75, 78) 36 30 
Proteus et rel. 90 76 (83, 67) 41 35 
Pseudomonas 90 90 (83, 100) 77 45 
Serratia 100 95 (92, 100) 77 70 
Yersinia et rel. 95 86 (83, 89) 72 60 
Spirochaetes Brachyspira 19 38 (50, 22) 9 0 
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Fig. 4.6. Score plot of the PCA, centered by species and grouped by samples, of the microbiota composition 
of centenarians (C, green circles), elderly (E, blue squares), and offspring of the centenarians (F, pink boxes). 
Explanatory variables are indicated by red triangles. First and second ordination axes are plotted, explaining 
together the 31% of the variability in the considered dataset. Log transformed data were used for the 
analysis. 
 
4.2 The “Centenarians project”: immunological profile 
 
 4.2.1 Immunophenotyping analysis 
In order to assess how the immune system changes in the age groups, we performed a 
cytofluorimetric quantification of the major lymphocytes populations in the peripheral blood of all 
subjects, with particular attention to the T-cell compartment. The percentages of naïve, central 
memory, effector memory, terminal effector cells were measured by flow cytometry in the main 
lymphocyte population (T helper and T cytotoxic cells). To identify these lymphocyte subsets an 
electronic gate was set on CD4+ and CD8+ T cells and the expression of CD45RA versus CCR7, 
CD28, and CD25 was analyzed on each main T-cell subset. Since the immunophenotype of subjects 
belonging to groups E and F did not differ for any of the analyzed lymphocytes population (data not 
shown), group S (seventy years old people) was defined, comprehending F and E subjects, and used 
for further analysis. Regarding B and T lymphocytes, no difference was found among age groups 
(data not shown). The other results are showed in Table 4.4.  
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The percentage of naive cytotoxic and helper T lymphocytes significantly decreased with age, 
whereas central memory T helper and T cytotoxic lymphocytes significantly increased. For effector 
memory T cytotoxic lymphocytes a significant increase in group Y in comparison to C and S was 
observed. Terminal effector helper T lymphocytes decreased significantly in C in comparison to 
both S and Y. Effector cytotoxic and helper T lymphocytes (CD28-) increased significantly in 
groups S and C with respect to Y. On the contrary, activated T cytotoxic lymphocytes were 
significantly higher in C with respect to both S and Y groups. 
 
 4.2.2 Evaluation of the inflammatory status 
In order to explore the inflammation level of the subjects involved in this study, plasmatic levels of 
the major pro- and anti-inflammatory cytokines were evaluated (Table 4.5). The pro-inflammatory 
cytokines IL-6 and IL-8 increased in C with respect to S and Y. In the case of IL-6 the increase was 
significant (CvsS, P = 0.003; CvsY, P = 0.05). On the contrary, IL-1  and TNF-  levels were 
significantly lower in C in comparison to Y (IL-1 , P = 0.03; TNF-  P = 0.03 . IL-1  and IFN-
levels did not change significantly in the different age groups. Regarding anti-inflammatory 
cytokines (TGF- 1 and IL-10), no significant differences were observed among the age groups. 
Moreover, the plasmatic levels of IL-2 and IL-12 which play an important role in activating the 
immune response, showed a decrease in C with respect to S and Y, which was significant in the case 
of IL-2 (CvsY, P = 0.04). 
The calculation of the inflammation score (Table 4.6) highlighted that most of the centenarians in 
this study (69.2%) were characterized by highly inflamed status, whereas in groups S and Y the 
majority of the subjects fell in the “low inflammation” group (S, 66.7%; Y, 75%). The difference in 
the proportion of highly inflamed subjects was significant when groups C and S (χ2 test, P = 0.05), 
and C and Y (χ2 test, P = 0.03) were compared. 
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Table 4.4 Immunophenotypical analysis of the main lymphocyte subsets involved in immunosenescence. 
Naïve, central memory, effector memory, terminal effector, effector (CD28-) and activated T lymphocytes are 
expressed as percentage of T helper and T cytotoxic lymphocytes. Data are expressed as mean percentage ± 
S.E.M. 
Lymphocyte subsets 
Mean (%) P value 
C S Y C vs S S vs Y C vs Y 
Naïve T lymphocytes 
(CD45RA+CCR7+) 
T helper 15.3±2.5 22.5±1.3 33.1±2.0 0.008 <0.0001 <0.0001 
T cytotoxic 12.9±1.4 15.7±1.2 33.9±2.3 / <0.0001 <0.0001 
Central Memory T 
lymphocytes (CD45RA-
CCR7+) 
T helper 34.8±3.5 21.5±1.9 13.7±1.1 <0.001 0.009 <0.0001 
T cytotoxic 11.4±1.2 9.8±1.5 5.0±0.6 / 0.03 <0.0001 
Effector Memory T 
lymphocytes (CD45RA-
CCR7-) 
T helper 42.2±2.8 40.8±1.7 37.8±2.2 / / / 
T cytotoxic 47.3±3.5 42.5±2.0 33.4±2.3 / 0.007 0.002 
Terminal Effector T 
lymphocytes 
(CD45RA+CCR7-) 
T helper 7.6±1.1 15.2±1.6 15.4±0.7 0.03 / <0.0001 
T cytotoxic 28.5±3.9 32.0±2.6 27.7±2.2 / / / 
Effector T lymphocytes 
(CD28-) 
T helper 10.7±2.0 9.5±1.6 3.5±1.2 / < 0.001 0.001 
T cytotoxic 48.2±5.4 49.8±3.7 28.6±4.4 / 0.002 0.02 
Activated T lymphocytes 
(CD25+) 
T helper 26.6±2.6 23.8±1.5 29.2±1.8 / 0.03 / 
T cytotoxic 13.3±2.9 6.6±0.7 5.5±0.4 0.003 / 0.001 
 
 
 
Table 4.5. Plasmatic levels of pro-  and anti-inflammatory cytokines. 
Cytokines 
Mean ± S.E.M. P value 
C S Y C vs S S vs Y C vs Y 
IL-6 (pg/ml) 61.4±18.9 24.6±6.2 20.9±4.3 0.003 / 0.05 
IL-8 (pg/ml) 30.4±7.8 22.0±4.2 21.9±4.1 / / / 
IL-1α (pg/ml) 1.7±0.6 3.0±0.6 3.0±0.7 / / 0.03 
TNF-α (pg/ml) 12.2±3.6 22.9±6.4 17.8±4.5 / / 0.03 
IFN-γ (pg/ml) 8.1±1.9 15.5±3.0 13.9±2.7 / / 0.08 
IL-1β (pg/ml) 1.3±0.3 1.7±0.3 1.5±0.2 / / / 
TGF-β1 (ng/ml) 5.6±0.8 6.2±0.9 5.5±0.7 / / / 
IL-10 (pg/ml) 1.7±0.2 2.1±0.3 2.3±0.6 / / / 
IL-2 (pg/ml) 18.8±4.6 30.0±4.6 27.2±5.4 / / 0.04 
IL-12p70 (pg/ml) 4.4±1.4 6.8±1.7 7.3±2.1 / / / 
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Table 4.6. Mean inflammatory score values in C, S, and Y group, and percentage of subjects in the two 
different inflammation categories. *P value<0.05. Distribution was analyzed using Chi Square test. 
Age group 
Mean 
inflammatory 
score 
Inflammatory score distribution 
low inflammation 
(0-4) 
high inflammation 
(5-8) 
C 4.8 33.3% 67.7% 
S 4.0 69.2%* 30.8%* 
Y 3.3 75%* 25%* 
 
 
 
4.3 The “Centenarians project”: correlation between cytokines level and gut microbiota. 
 
In order to individuate correlations between the microbiota composition and the cytokines pattern, 
log-transformed results of pro-inflammatory cytokines quantification and HITChip profiling of the 
gut microbiota were used in a multivariate analysis, using cytokines quantification and the age 
groups as environmental variables. RDA shows that 8.9% of the total variability of the gut 
microbiota can be related to the pro-inflammatory cytokines pattern (Fig. 4.7). Relations shown in 
the plot are statistically significant, as established by the MCPP (P = 0.014). In accordance with 
previous analyses (Fig. 4.2), the centroid of group C is plotted distant from both the S and Y 
centroid, highlighting the similarity in the gut microbiota asset and relation with the inflammatory 
status between elderly and young adults. 
Several bacteria belonging to the phylum Proteobacteria seemed to be positively correlated with IL-
6 and IL-8. IL-8 was correlated with Alcaligenes faecalis et rel., Leminorella, and Proteus et rel., 
while IL-6 was correlated with Escherichia coli et rel., Haemophilus, Klebsiella pneumoniae et rel., 
Pseudomonas, Serratia, Yersinia et rel., and Vibrio. IL-8 and IL-6 were correlated also with 
Bacillus (Bacilli), Egghertella lenta et rel. (Actinobacteria), and Eubacterium cylindroides et rel. 
(Clostridium cluster XIVa). On the other side, Eubacterium hallii et rel., Eubacterium ventriosum et 
rel., Eubacterium rectale et rel., Clostridium nexile et rel., and Outgrouping Clostridium cluster 
XIVa (all belonging to the Clostridium cluster XIVa) are inversely correlated with IL-6 and IL-8. 
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Fig. 4.7. Triplot of the RDA showing the relation between the microbiota composition, the pro-inflammatory 
cytokines levels and the age of the subjects. Cytokines level (red arrows) and age groups (C, S, and Y, red 
triangles) are used as linear and nominal environmental variables, respectively. Samples belonging to C, S 
and Y groups are indicated by green circles, blue squares and yellow diamonds, respectively. Responding 
bacterial subgroups that explained more than 20% of the variability of the samples are indicated by black 
arrows. First and second ordination axes are plotted, showing 5.8% and 3.1% of the variability in the dataset. 
Red arrows which are not labelled corresponds to (clockwise, starting from the left) TNF-α, IFN-γ, IL2, 
IL1α, IL12p70, and IL1β. Bottom-left, P value obtained by MCPP is reported. 
 
 
Pearson’s correlation analysis of the log transformed level 2 HITChip data and cytokines revealed 
significant Pearson’s r for IL-6 and IL-8 (Table 5). All the bacterial groups which exhibited a slight 
positive correlation with either IL-6 or IL-8 (ranging between 0.41 and 0.55) belonged to the 
phylum Proteobacteria. Interestingly, only one bacterial group, Ruminococcus lactaris et 
al.(Clostridium cluster XIVa), has been found with a slight negative correlation with IL-8 (-0.44, P 
= 0.0001). 
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Table 4.7. Relevant Pearson’s correlations between microbiota components and the pro-inflammatory 
cytokines IL6 and IL8. 
 
Bacterial group 
IL-6 IL-8 
Pearson's r P value Pearson's r P value 
Alcaligenes faecalis et al. / / 0.43 00.02.00 
Escherichia coli et rel. 0.46 < 0.0001 0.35 0.003 
Haemophilus 0.47 < 0.0001 0.24 0.04 
Klebsiella pneumoniae et rel. 0.47 < 0.0001 / / 
Leminorella 0.26 0.02 0.41 < 0.0001 
Proteus 0.32 0.007 0.55 < 0.0001 
Pseudomonas 0.45 < 0.0001 / / 
Serratia 0.45 < 0.0001 0.23 0.05 
Vibrio 0.45 < 0.0001 0.28 0.02 
Yersinia 0.48 < 0.0001 0.33 0.005 
Ruminococcus lactaris et rel. -0.32 0.006 -0.44 0.0001 
 
 
 
4.4 Design and construction of the HTF-Microb.Array. 
 
 4.4.1 Target selection and probe design 
The rational selection of the HTF-Microb.Array targets was carried out using a phylogenetic 
approach. To this aim we implemented the 16S rRNA database of the ARB Project (release 
February, 2005) with the 16S rRNA gene database of the RDP available at the time and a 
phylogenetic tree was constructed. Based on the tree nodes, 30 phylogenetical groups of the human 
intestinal microbiota were rationally selected as the target group for the HTF-Microbi.Array 
(Appendix 1). The selected groups belonged to different phylogenetic levels (species, genus, family, 
cluster, or group of species indicated by the warding “et rel.”). The entire list of the array targets is 
represented in Tab. 4.8. For part of the division Firmicutes, the target selection was carried out 
based on the classification proposed by Collins et al (1994). Clostridium cluster I and II, 
Clostridium cluster IX, Clostridium cluster XI, and Clostridium cluster XIVa were selected. For the 
Clostridium cluster IV, four subgroups of species were defined: Ruminococcus albus et rel., 
Ruminococcus bromii et rel., Faecalibacterium prausnitzii et rel., and Oscillospira guillermondii et 
rel. Within the Firmicutes division, the family Lactobacillaceae, and the groups Bacillus clausii et 
rel., Bacillus subtilis et rel., Bacillus cereus et rel., Enterococcus faecalis et rel., and Enterococcus 
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faecium et rel. were also selected. Other selected groups were the Bacteroides/Prevotella cluster 
(division Bacteroidates), the family Bifidobacteriaceae (division Actinobacteria), the family 
Enterobacteriaceae and the genus Campylobacter (division Proteobacteria). For clusters or 
families, relevant species, genera or subgroups of species were selected to design “sub-probes”. The 
genus Veillonella was selected for Clostridium cluster IX, the species Eubacterium rectale for 
Clostridium cluster XIVa, Clostridium difficile for Clostridium cluster XI, and Clostridium 
perfringens for Clostridium cluster I and II. The group Bifidobacterium longum et rel. was chosen 
for the family Bifidobacteriaceae, and the genera Yersinia and Proteus for the Enterobacteriaceae. 
Specificity and coverage of each candidate probe was assessed by using the tool Probe Match of the 
RDP database. The probe pairs selected for the HTF-Microbi.Array were required to perfectly 
match the sequences of the positive set and to possess at least a mismatch at the 3’ end of the 
discriminating probe respect to the entire negative set. The designed probes pairs had an average 
melting temperature (Tm) of 67.8 ± 0.9 °C (n=60) and an average length of 35.6 ± 4.9 nucleotides. 
Sixteen out of the 30 probe pairs were characterized by having no degenerated bases, whereas only 
one probe pair (i.e. the one for Clostridium cluster I and II) had 4 and 3 ambiguous bases on DS and 
CP, respectively (Appendix 2). 
 
 4.4.2 Validation of LDR probe pair specificity 
The specificity of the designed LDR probe pairs was tested by using 16S rRNA PCR amplicons 
from 28 microorganisms members of the human intestinal microbiota. Amplicons were prepared by 
amplification of genomic DNA. Proving the specificity of the HTF-Microbi.Array, all the 16S 
rRNA amplicons were properly recognized in separate LDR hybridization reactions with the entire 
probe set of the array. Two replicated independent LDR-UA experiments were performed with an 
optimal reproducibility. For each of the 16S rRNA template only group-specific spots, and spots 
corresponding to the hybridization controls showed positive signals (P<0.01) (Appendix 3). As a 
negative control, we performed two independent PCR-LDR-UA experiments using double distilled 
water, instead of genomic DNA, as sample. As expected, no positive signal was detected. The ratio 
between the signal intensities of the specific probes and the blank intensity (SNRs) averaged 
206.9±185.7, whereas the ratio between all the other probes and the blank intensity (SNRns) 
averaged 2.1±1.4. Therefore, the ratio between specific and non-specific probes resulted more than 
100 fold on average. 
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Table 4.8 Probe set of the HTF-Microbi.Array. For each probe is indicated the spot number (N.), the 
phylogenetic level, the phylogeny of the target group (cluster, order, division), and the ecology in the 
gastrointestinal ecosystem [mutualistic (M), opportunistic (O), pathogen (P)]. The relative abundance in a 
healthy gut ecosystem of the principal microbial groups is also indicated. B., Bifidobacterium; L., 
Lactobacillus; Cl, Clostridium cluster. 
      
PROBE N. 
PHYLOGENETIC  
LEVEL 
CLUSTER DIVISION ECO 
Bacteroides/Prevotella 16 Cluster Bacteroides/Prevotella Bacteroidetes M 
Ruminococcus bromii 38 Sub cluster Cl IV Firmicutes M 
Ruminococcus albus 39 Sub cluster Cl IV Firmicutes M 
Faecalibacterium 
prausnitzii 
40 Sub cluster Cl IV Firmicutes M 
Oscillospira 
guillermondii 
41 Sub cluster Cl IV Firmicutes M 
Clostridium IX 37 Cluster Cl IX Firmicutes M 
Veillonella 20 Genus Cl IX Firmicutes M 
Clostridium XIVa 22 Cluster Cl XIVa Firmicutes M 
Eubacterium rectale 19 Species (et rel) Cl XIVa Firmicutes M 
Bifidobacteriaceae 25B Family Bifidobacterium Actinobacteria M 
B. longum 3 Species (et rel) Bifidobacterium Actinobacteria M 
Lactobacillaceae 21B Family Lactobacillaceae Firmicutes M 
L. plantarum 33 Species (et rel) Lactobacillaceae Firmicutes M 
L. casei 12 Species (et rel) Lactobacillaceae Firmicutes M 
L. salivarius 14 Species (et rel) Lactobacillaceae Firmicutes M 
Bacillus clausii 32 Species (et rel) Bacillaceae Firmicutes M 
Bacillus subtilis 8 Species (et rel) Bacillaceae Firmicutes M 
Fusobacterium 15 Genus Fusobacteriaceae Fusobacteria M 
Cyanobacteria 42 Family Cyanobacteria Cyanobacteria M 
Clostridium XI 36 Cluster Cl XI Firmicutes O 
Clostridium difficile 18 Species (et rel) Cl XI Firmicutes O 
Clostridium I and II 35 Cluster Cl I and II Firmicutes O 
Clostridium perfringens 17 Species (et rel) Cl I and II Firmicutes O 
Enterococcus faecalis 9 Species (et rel) Enterococcales Firmicutes O 
Enterococcus faecium 10 Species (et rel) Enterococcales Firmicutes O 
Bacillus cereus 7 Species (et rel) Bacillaceae Firmicutes P 
Enterobacteriaceae 23B Family Enterobacteraceae Proteobacteria O/P 
Yersinia enterocolitica 4 Species (et rel) Enterobacteraceae Proteobacteria O/P 
Proteus 5 Genus Enterobacteraceae Proteobacteria O/P 
Campylobacter 6 Genus Campylobacteraceae Proteobacteria P 
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 4.4.3 Evaluation of the LDR sensitivity and relative abundance detection level 
In order to define the detection limits of the HTF-Microbi.Array, LDR-UA experiments were 
carried out with different concentrations of an artificial mix of 16S rRNA amplicons from 6 
members of the human intestinal microbiota. The 16S rRNA amplicons from Bacillus cereus, 
Lactobacillus casei, Bifidobacterium adolescentis, Ruminococcus albus, Prevotella, Y. 
enterocolitica were all specifically recognized in a range of concentrations from 0.7 to 75 fmol 
(P<0.01), demonstrating the high sensitivity and specificity of the array (Fig. 4.8). Subsequently, in 
order to evaluate the relative abundance detection level of the HTF-Microbi.Array, LDR-UA 
experiments were performed on hybridization mixes containing low quantities of Escherichia coli 
PCR products and increasing amounts of human genomic DNA. This is a fundamental issue in the 
case of single species present in the gut microbiota at very low fractional abundance. According to 
our data, 1 fmol of E. coli amplicon was sufficient (p<0.005) to be detected in all the tested 
conditions (from up to 6.3 μg of human gDNA). Considering the PCR product as a ~ 1700 bp 
amplicon, 1 fmol corresponds to 1.2 ng and, thus, the sensitivity limit results 0.02%. 
 
4.5 Validation of the HTF-Microb.Array on human fecal microbiota. 
 
 4.5.1 Characterization of the faecal microbiota of eight healthy young adults 
The HTF-Microbi.Array was applied in a pilot study for the characterization of the faecal 
microbiota of eight young adults. For all subjects faecal DNA was extracted, total bacterial 16S 
rRNA amplified, and two separate LDR-UA experiments were carried out. For each sample a 
profile of presence-absence probes response was obtained. The cluster analysis of the phylogenetic 
fingerprints showed that, with the exception of subject n. 2, samples from the same subject 
clustered together, demonstrating a good reproducibility of the microbiota fingerprints obtained 
using the HTF-Microbi.Array (Fig. 4.9). 
 
 
 
Fig. 4.8. (following page) LDR-universal array experiments carried out on a complex mix of 16 rRNA 
amplicons obtained from six members of the human intestinal microbiota: B. cereus (B.c.), L. casei (L.c.), 
B. adolescentis (B.a.), R. albus (R.a.), Prevotella (Pr.), Y. enterocolitica (Y.e.).  Amplicons were tested 
in a concentration ranging from 0.7 to 75 fmol. Green bars indicate the fluorescence intensity (IF) of each 
probe. Blue stars over the fluorescence bars indicate the probes that gave a positive response with a P value 
<0.01. Red dots indicate that one or two replicates out of four for each ZipCode were excluded because 
having an IF < 2.5 times the average of the spots. Blue bar corresponds to the hybridization positive control 
signal. Black, red and purple bar correspond to the negative controls signals. 
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(B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 0.7 fmol (B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 1.5 fmol
(B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 3 fmol (B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 6 fmol
(B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 12 fmol (B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 25 fmol
(B.c-L.c-B.a-R.a-Pr-Y.e) 16S rDNA 50 fmol
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As expected, the major mutualistic symbionts of the human intestinal microbiota, such as 
Bacteroidetes and the members of the Clostridium cluster IV and XIVa, were represented in the 
faecal microbiota of all the subjects. With the exception of B. clausii et rel., minor mutualistic 
symbionts such as Actinobacteria, Lactobacillaceae, B. subtilis et rel., Fusobacterium, and 
Cyanobacteria were detected only in different sub-fractions of the subjects. In particular, subjects n. 
17, 15, 4, and 1 were characterized by the presence of Fusobacterium. Subjects n. 4, 15 and 17 
possessed B. subtilis et rel., while subjects n. 4, 1, 9, 16 and 5 harboured Cyanobacteria in their 
faecal microbiota. On the other hand, only a fraction of the subjects, clustering on the left side of 
the map, presented opportunistic pathogens in their faecal microbiota. Subjects n. 17, 15 and 4 
presented both Proteus and E. faecalis et rel., while in subject n. 15 members of the Clostridium 
cluster I and II and Yersinia enterocolitioca et rel. were also detected. 
For each subject the relative fluorescence intensity (IF) contribution of each HTF-Microbi.Array 
probes, in terms of percentage of the total IF, was also calculated (Fig. 4.10). The mean of IF data 
from both the LDR-UA experiments were considered. Even if all subjects were characterized by a 
specific individual profile, a common trend can be found by comparing the comprehensive relative 
IF contribution of probes targeting major mutualistic symbionts (Bacteroides/Prevotella, 
Clostridium clusters IV, IX, and XIVa), minor mutualistic symbionts (Bifidobacteriaceae, 
Lactobacillaceae, B. clausii et rel., , B. subtilis et rel., Fusobacterium, and Cyanobacteria), and 
opportunistic pathogens (Clostridium clusters I and II, IX, E. faecalis et rel., E. faecium et rel., B. 
cereus et rel., Enterobacteriaceae, Yersinia enterocolitica et rel., Proteus, Campylobacter). In 
particular, for all subjects the highest relative IF contributions were obtained for major mutualistic 
symbionts. The contribution of Bacteroides/Prevotella ranged between 8-37%, whereas the 
contribution of Clostridium clusters IV, IX, and XIVa ranged between 17-34%, 3-15%, and 5-29%, 
respectively. Differently, minor mutualistic symbionts were characterized by lower values of 
relative IF contributions. Bifidobacteriaceae contributed for the 0.5-3.1%, Lactobacillaceae for the 
1.5-9.4%, B. clausii et rel. for the 4-13%, B. subtilis et rel. for the 0.6-2.5%, Fusobacterium for the 
1.2-4.4%, and Cyanobacterium for 0.6-4.5%. As expected, opportunistic pathogens showed together 
the lowest relative IF contribution in all the subjects under study (from 5 to 10%). 
 
 
 
Fig. 4.9. (Following page) Cluster analysis of the phylogenetic fingerprint of 16 faecal samples from 8 
young adults. Response of each of the HTF-Microbi.Array probes for what concerns presence/absence of the 
target group is shown: positive response in red (P<0.01), negative responses in blue (P>0.01). Gray lines 
below the samples indicate adjacent replicated LDR of the same sample. 
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Fig. 4.10. (Previous page) IF relative contribution of targeted groups to the total microbiota. For each sample 
the entire HTF-Microbi.Array probe set was considered and their relative IF contribution was calculated as 
percentage of the total IF. Sub-probes were excluded and, for each subject, data from two separate LDR-
universal array experiments were taken onto consideration. The averaged IF from both the LDR-Universal 
Array experiments was considered. The principal intestinal groups of major mutualistic symbionts are 
indicated: Bacteroides/Prevotella (B/P) blue, Clostridium cluster IV (Cl.IV) green, Clostridium cluster IX 
(Cl.IX) brown, Clostridium cluster XIVa (Cl.XIVa) dark brown. Lactobacillus, B. clausii, B. subtilis, 
Fusobacterium and Cyanobacteria are grouped as minor mutualistic symbionts (minor) indicated in yellow. 
Opportunistic pathogens (opp) are indicated in red. 
 
 
 
 
4.6 Comparison of the two microarray approaches. 
 
The fecal microbiota of six of the centenarians involved in the “Centenarians project” was analyzed 
by using HTF-Microb.Array, in order to compare the two microarray approaches presented here. 
Following the procedure showed in Fig. 4.5 and 4.10, the average relative IF contribution, in terms 
of percentage of the total IF, was calculated and compared to the average relative contribution of the 
level 1 phylogenetic groups obtained for the same six centenarians with the HITChip analysis (Fig. 
4.11). Because of the completely different approach used for the design of the two diversity 
microarrays, approximations were performed to make the results comparable. The IF contribution 
of the Entorobacteriaceae probe was approximated to the one of the Proteobacteria in the HITChip 
profile, even if the phylum Proteobacteria comprehends many more families. Similar approximation 
was performed to compare the IF contribution of the Bifidobacteriaceae probe and the contribution 
of the phylum Actinobacteria. The contribution of Bacilli in the HITChip profiling was considered 
equal to the sum of the IF contribution of the probes B. clausi et rel., B. cereus et rel., B. subtilis et 
rel., and Lactobacillaceae on the HTF-Microb.Array. The contribution of Clostridium cluster IV 
was considered equal to the sum of the IF contribution of the four probes in which this Clostridium 
cluster had been split during the HTF-Microb.Array design (F. prausnitzii et rel., O. guillermondii 
et rel., R. bromii et rel., R. albus et rel.). 
The HTF-Microb.Array seems to underestimate the presence of bacteria of the Clostridium cluster 
XIVa with respect to the HITChip profiling. On the contrary, the other main Clostridium clusters 
(IV, IX, and XI) seem slightly overestimated, probably as a consequence of the previous 
observation. The relative IF contributions of Enterobacteriaceae, Bacteroides/Prevotella, and 
Bacilli appear to be comparable to the relative contribution of Proteobacteria, Bacteroidetes and 
Bacilli on the HITChip profiling. The relative contribution of Actinobacteria to the HITChip profile 
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is slightly higher than the IF relative contribution of the Bifidobacteriaceae probe on the HTF-
Microb.Array, due to the fact that the gut microbiota contains more Actinobacteria families 
alongside to the Bifidobacteriaceae. Finally, the contribution of the Fusobacteria is clearly 
overestimated by the HTF-Microb.Array analysis, when compared to the HITChip profiling. 
 
 
Fig 4.11. Relative contribution of the level 1 phylogroups to the fecal microbiota obtained by HITChip 
profiling, and relative IF contribution to the total IF obtained by HTF-Microb.Array analysis, of six 
centenarians. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HITChip HTF-Microb.Array
Proteobacteria
Fusobacterium
Clostridium XIVa
Clostridium XI
Clostridium IX
Clostridium IV
Bacteroidetes
Bacilli
Actinobacteria
Discussion 
67 
 
5. 
DISCUSSION 
 
 
5.1 The “Centenarians project” 
 
 5.1.1 General remarks 
The “Centenarians project” aimed the study of the age-related changes in both the gut microbiota 
and the inflammatory status during the whole adult life, starting from young adults (30 years old in 
average), through elderly (70 years old), to the extreme limit of the human lifespan, represented by 
a group of centenarians. 
The exceptionality of this comparative study resides in the introduction of this third, extremely 
aged, population, alongside to young and elderly adults, the two age groups addressed by the 
studies published until now (Bartosch et al, 2004; Woodmansey et al, 2004; Mariat et al, 2009; 
Rajilic-Stojanovic et al, 2009). This peculiarity allowed us to highlight that changes in the gut 
ecosystem, in terms of composition and diversity, do not follow a linear relation with age. In fact, 
the difference between the gut microbiota of young adults and elderly, separated by more than 40 
years in average, is remarkably small if compared to the difference observed between centenarians 
and elderly, separated by less than 30 years of life. 
Young and elderly adults show a very comparable overall structure of the gut microbiota, which 
confirms the most recent characterizations, with Bacteroidetes and Firmicutes highly dominant 
(contributing for approximately 95% to the microbiota), and smaller fractions of  Actinobacteria, 
and Proteobacteria (Ley et al, 2006; Andersson et al, 2008; Tap et al, 2009). The diversity values of 
the gut microbiota of elderly and young adults were found comparable (average Simpson index 
149.3 and 162.8, respectively), and fits the range of diversity expected for healthy adults (Simpson 
index = 150-200) (A. Salonen and W. de Vos, personal communication). 
On the other hand, centenarians come into view as a separate population, whose microbiota shows 
an organization which significantly differs from the adult-like pattern, and a low diversity in terms 
of species composition (Simpson index = 127). Bacteroidetes and Firmicutes still dominate the gut 
microbiota of extremely old people (93%), but a change in the relative proportion of Firmicutes 
subgroups was found, with a decrease in the contributing Clostridium cluster XIVa, an increase in 
Bacilli and a rearrangement of the Clostridium cluster IV composition. Moreover, the gut 
microbiota of centenarians is enriched in Proteobacteria, a group containing many of those bacteria 
recently redefined as “pathobionts”, referring to minor opportunistic components of the human gut 
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ecosystem that, under some circumstances, e.g. inflammation, may escape surveillance, overtake 
mutualistic symbionts and induce pathology (Sansonetti and Di Santo, 2007; Round and 
Mazmanian, 2009). 
The structure of the gut microbiota is well known to be relatively stable through adulthood 
(Vanhoutte et al, 2004; Leser and Molbak, 2009). Our findings suggest that this stability may last 
longer than expected, and that the ageing process starts to affect the gut microbiota later than 65 
years old, which is the usual threshold age for being defined as “elderly”. 
Up to now, only few studies were published focusing on the molecular characterization of the gut 
ecosystem in the elderly. In general, these studies reported compositional differences comparing 
groups of young adults (20-50 years old) to elderly with a wide interval of age, ranging from 60 to 
95 years old approximately (Bartosch et al, 2004; Mueller et al, 2006; Mariat et al, 2009). 
Conversely, thanks to a narrower range of age for the recruited elderly (63-78 years old), and the 
introduction of the “third point” of the analysis (centenarians), we could provide a higher resolution 
on the effects of ageing on the gut microbiota. This approach indicates that the threshold for an 
“aged” microbiota should be moved to the age of 75-80 years. 
Recently, Rajilic-Stojanovic et al (2009) used the HITChip technology to highlight differences 
between the fecal microbiota of 5 young adults and 5 elderly from Northern Europe, aged 71 years 
in average. An age-related increase in the number of Bacilli, and a decrease in bacterial groups 
belonging to the Bacteroidetes were reported. Interestingly, these differences between elderly and 
young adults were not confirmed by our HITChip study, where only centenarians showed 
significantly higher proportions of Bacilli, and the Bacteroidetes population remained unchanged 
among the age groups. A fascinating explanation of this discrepancy may reside in the demographic 
and geographic differences between the study population, also defined as country specificity, which 
has been reported to strongly affect the age-related changes in the gut microbiota composition 
(Mueller et al, 2006). 
 
 5.1.2 The gut microbiota of centenarians 
Our experimental data provide a view of a centenarian gut ecosystem characterized by a lower 
relative contribution of Clostridium cluster XIVa, than in younger people. The general decrease in 
the abundance of Eubacterium rectale - Clostridium coccoides group, corresponding to the 
Clostridium cluster XIVa, has already been described as an effect of the ageing process (Hayashi et 
al, 2003; Mueller et al, 2006; Zwielehner et al, 2009). 
On the other hand, our results showed that the proportion of Clostridium cluster IV in the total 
microbiota is comparable in all the subjects, but the proportions of different phylotypes within the 
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cluster differ significantly between the age groups, suggesting a rearrangement in the composition 
of Clostridium cluster IV in centenarians. 
In particular, our results showed a rearrangement in the population of butyrate producer bacteria in 
centenarians, with respect to the microbiota of younger people. Butyrate is a short chain fatty acid 
(SCFA) mainly produced in the gut by Firmicutes of the Clostridium clusters IV and XIVa 
(Barcenilla et al, 2000; Pryde et al, 2002; Louis and Flint, 2009). Butyrate producers are receiving a 
growing interest in the gut ecology, as this SCFA represents a major energy source for the 
enterocytes and may be implicated in the protection against inflammatory bowel diseases (IBD) 
(Thibault et al, 2009). In our study, several butyrate producers were found in lower amounts in 
centenarians than in the other age groups. These included Ruminococcus obeum et rel., Roseburia 
intestinalis et rel., Eubacterium ventriosum et rel., Eubacterium rectale et rel., and Eubacterium 
hallii et rel. (belonging to the Clostridium cluster XIVa), and Papillibacter cinnamovorans et rel., 
and Faecalibacterium prausnitzii et rel. (belonging to the Clostridium cluster IV). Conversely, the 
butyrate producers Anaerotruncus colihominis et rel., and Eubacterium limosum et rel. increased in 
centenarians. Interestingly, E. limosum, a species with anti-inflammatory effects (Kanauchi et al, 
2006), shows the highest mean differences between centenarians and both elderly (ratio 16.2) and 
young adults (ratio 14.5).   
F. prausnitzii is a species of particular interest for the gut inflammation processes, able to exert also 
a butyrate-independent anti-inflammatory effect (Sokol et al, 2008, Sokol et al, 2009), and it is 
already known to decrease in the elderly (Mueller et al, 2006, Zwielehner et al, 2009). 
Another feature of the centenarians gut ecosystem is the increase in facultative anaerobes, such as 
bacteria belonging to the groups Fusobacterium, Bacillus, Staphylococcus, Corynebacterium, 
Micrococcaceae, and many members of the phylum Proteobacteria. Such opportunistic species, 
especially Enterobacteriaceae, thrive in an inflamed environment (Pédron and Sansonetti, 2008; 
Sansonetti and Medzhitov, 2009), and are known to increase both in elderly and people affected by 
IBD (Guigoz et al, 2008; Sartor, 2008). 
The decrease in the amount of health promoting bacteria, in particular bifidobacteria, is another well 
reported effect of age (Woodsmansey et al, 2004; Mueller et al, 2006). In our study, we detected a 
significant decrease of bifidobacteria in centenarians when compared to young adults, only by using 
specific real time PCR. Discrepancies between results obtained by different methods used for 
quantification of bifidobacteria in feces have been reported, not only when viable counts are 
compared with results obtained by molecular techniques (Sghir et al, 2000; Hopkins et al, 2001), 
but also when two different molecular techniques are compared (Tap et al, 2009). 
Interestingly, we found increased levels of the mucin degrading A. muciniphila in aged people if 
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compared to the young adults, contrasting the earlier results obtained by Collado et al (2007), who 
demonstrated that A. muciniphila counts decline with the age. Again, the country-specificity of the 
age-related changes in the gut microbiota may be the cause of this discrepancy, as well as 
differences in the diet of the aged people, that may favour populations of bacteria able to degrade 
mucins. 
The centenarians involved in this study, representative of this exceptionally aged population, were 
obviously very frail and inflamed (Baggio et al, 1998; Passeri et al, 2003). This could explain why 
some of the differences found between centenarians and elderly, such as the decrease in F. praunitzii 
and the increase in Enterobacteriaceae, were reported also between elderly with high and low 
frailty score (Van Tongeren et al, 2005). 
 
 5.1.3 Gut microbiota and inflamm-aging 
The fecal microbiota of centenarians shows all the features of a partially compromised ecosystem, 
whose balance with the immune system is likely to be upset.  The immune system of these very old 
people deteriorates under the effect of the immunosenescence, a progressive age-related 
remodelling of the immune functions, where several functions are reduced, others remain 
unchanged, or even increase (Franceschi et al, 1995). The careful immunophenotyping we 
performed, allowed us to confirm that the major, expected age-related changes of the T cells 
compartment are present in the enrolled subjects, including centenarians (Fagnoni et al, 2000; Zanni 
et al, 2003; Alberti et al, 2006; Nasi et al, 2006; Koch et al, 2008), suggesting that the population 
here considered represents a suitable sample to investigate the possible relationship between gut 
microbiota composition and immune/inflammatory status. One of the major characteristics of 
immunosenescence is the progressive development of a chronic, low grade inflammatory status 
called inflamm-ageing ( Franceschi et al, 2000a; Franceschi, 2007a; Franceschi et al, 2007b). In our 
study population, the proportion of centenarians showing a high inflammation score was 
significantly higher than in the other age groups, confirming the inflamm-aging hypothesis. 
The parallel analysis of the gut microbiota composition and the inflammatory parameters shows that 
the increase in pro-inflammatory cytokines in the peripheral blood correlates with changes in the 
gut microbiota profile of centenarians. In particular, the increase of IL-6 and IL-8 was linked with 
the enrichment in Proteobacteria, whereas it seemed to be correlated with a decrease in the amount 
of some butyrate producing bacteria, such as E. rectale, E. hallii, and E. ventriosum. This 
observation supports the hypothesis that the age-related changes of gut microbiota composition, 
particularly evident in centenarians, may either contribute to inflamm-aging (proliferation of 
opportunistic Proteobacteria to the detriment of symbionts Firmicutes and Bacteroidetes) or be 
Discussion 
71 
 
affected by the systemic inflammatory status. This hypothesis is supported by recent findings 
demonstrating that the inflammation shifts the balance between symbionts and pathobionts, on 
behalf of the seconds (Round and Mazmanian, 2009). 
However, an important characteristics of centenarians is that, despite their inflammatory status, they 
reached the extreme limit of human lifespan and escaped or delayed the major age-related diseases 
which share an inflammatory pathogenesis. This brings to the hypothesis that the inflammatory 
status may have been counterbalanced by other physiological events, in order to help the survival of 
this exceptional individuals. As for the gut microbiota, we demonstrated that there is a remodelling 
in the composition of the Firmicutes population in centenarians, in which some bacterial groups 
decrease and other increase. Among the decreasing Firmicutes, we found many species known to 
have anti-inflammatory properties (F. prausnitzii, and several butyrate producers), but other bacteria 
with unknown anti-inflammatory properties may be among the increasing ones. For instance, the 
remarkable increase of E. limosum in centenarians may be of particular interest, opening the way to 
fascinating hypotheses. According to the literature, E. limosum may positively contribute to the 
health status of an aged and inflamed intestine, thanks to its anti-inflammatory properties (Kanauchi 
et al, 2006), and its ability to convert dietary isoflavonoids into other phytoestrogens, such as 
genistein and daidzein (Hur and Rafii, 2000; Possemiers et al, 2008). Phytoestrogens are being 
intensively studied because of their potential protective role against the development of breast, 
prostate and colon cancer, and coronary heart diseases (Adlercreutz, 2002). Even if it remains 
speculative, a positive effect of E. limosum on the gut health may be possible according to the 
literature. 
 
5.2 The HTF-Microb.Array 
 
 5.2.1 Design and validation of the tool 
The HTF-Microb.Array is based on the Ligation Detection Reaction – Universal Aray (LDR-UA) 
approach, which is a fast and sensitive tool for the characterization of complex microbial 
communities (Castiglioni et al, 2004; Hultman et al, 2008). The use of this molecular technique 
allows overcoming the major limitations of DNA microarrays whose discriminative power is based 
on hybridization. In fact, i. optimization of the hybridization conditions for each probe set is not 
required; ii. problems due to the secondary structures of the target DNA are minimized, iii. steric 
hindrances of differentially sized nucleic acid hybrids formed on the array after the hybridization 
are decreased (Peplies et al, 2003). The final probe set of the HTF-Microb.Array allows a high 
taxonomic level fingerprint of the human intestinal microbiota, with a good coverage of the major 
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and minor components, as well as some of the most important pathogens and opportunistic bacteria 
(Jin et al, 2005). The LDR probes were designed by choosing discriminating (DS) oligonucleotides 
whose 3’end allowed the perfect discrimination of the target species from the non-target ones on the 
basis of our 16S rRNA sequence database. Definition of accurate and specific negative sets of gut 
microbiota sequences by ORMA tool allowed the selection of maximally discriminative probe pairs. 
Probe specificity was confirmed on the entire known 16S rRNA gene sequences environment by the 
RDP Probe Match tool. This requirement is fundamental, since the primer set used for the PCR 
amplification was the “universal” 16S rRNA primer set designed by Edwards et al (1989). 
The HTF-Microb.Array recognized without ambiguity the 16S rRNA amplicons obtained from 28 
members of the intestinal microbiota belonging to Bacteroides/Prevotella, Clostridium clusters IV, 
IX, XIVa, XI, I and II, Bifidobacteriaceae, Lactobacillaceae, Bacillus, Enterococcus, 
Enterobacteriaceae and Campylobacter, demonstrating the specificity of all the probe pairs. The 
sensitivity of the HTF-Microbi.Array was evaluated by using different concentrations of an 
artificial mix of 16S rRNA amplicons obtained from 6 microorganisms members of the human 
intestinal microbiota. All PCR products were specifically recognized in a concentration ranging 
from 75 to 0.7 fmol, showing high array sensitivity. The efficiency of the HTF-Microbi.Array in the 
detection of a particular target in a complex DNA environment was also determined. According to 
our data, the array is able to detect a specific DNA target down to 0.02% of the total 16S rRNA, 
which is comparable to the values obtained by Rajilic-Stojanovic et al. (2009) and Palmer et al. 
(2006). Thus the HTF-Microb.Array shows the potentiality to sense low abundant species of the 
gastrointestinal microbiota, enabling the detection of the 16S rRNA of a peculiar target group 
present at a fractional abundance <0.1% in an artificial mixture. 
 
 5.2.2 Validation of HTF-Microb.Array on human fecal samples 
The HTF-Microb.Array was used in a pilot study to characterize the faecal microbiota of eight 
young adults. Cluster analysis of the presence-absence probes profiles enabled the identification of 
a reproducible microbiota fingerprint for each subject at high taxonomic level. As expected, the 
intestinal microbial community of the volunteers in the study resembled the typical fingerprint of 
healthy adults (Rajilic-Stojanovic et al, 2007). According to our data, the faecal microbiota of the 
enrolled subjects was dominated by major mutualistic symbionts. In fact, members of 
Bacteroidetes, Clostridium clusters IV, IX and XIVa were all represented in 100% of the subjects. 
On the other hand, minor mutualistic symbionts, such as Lactobacillaceae, Bacillus subtilis et rel., 
Fusobacterium and Cyanobacteria, were detected in 55, 37, 50, and 63 % of the subjects, 
respectively. Opportunistic pathogens, such as Enterococcus faecalis et rel., members of the 
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Clostridium clusters I and II and of the Enterobacteriaceae, were represented only in 43, 25 and 
12% of the subjects, respectively. Most importantly, enteropathogens such as, Clostridium difficile, 
Clostridium perfringens, Enterococcus faecium et rel., Bacillus cereus et rel., and Campylobacter 
were never detected. A discrepancy between our data and the literature is the relatively low 
prevalence of the health promoting Bifidobacteriaceae in our samples (only 13% of samples). 
However, the low prevalence of bifidobacteria is a typical bias for several phylogenetic DNA 
microarrays (Palmer et al, 2007; Rajilic-Stojanovic et al, 2009). Probably this is due to the intrinsic 
low efficiency of amplification of the bifidobacterial genome with universal primer sets for the 16S 
rRNA gene (Hattori and Taylor, 2009). Surprisingly, a high prevalence was obtained for the minor 
mutualistic symbiont Bacillus clausii et rel., 100% of samples, and the opportunistic pathogen 
Proteus, 50% of samples. For each subject the relative fluorescence intensity (IF) contributions of 
the probes were calculated, obtaining an approximate evaluation of the relative abundance of the 
principal microbial groups of the faecal microbiota. In general agreement with previous 
metagenomic studies (Eckburg et al, 2005; Andersson et al, 2008; Peterson et al, 2008; Claesson et 
al, 2009; Hattori and Taylor, 2009) and SSU rRNA phylogenetic microarray investigations (Palmer 
et al, 2007; Rajilic-Stojanovic et al, 2009), mutualistic symbionts such as Bacteroidetes, 
Clostridium clusters IV, IX and XIVa largely dominated the faecal microbiota, contributing for the 
65 to 80% of total microbiota, depending on the subject. Differently, with an overall contribution 
ranging from 10 to 30%, minor mutualistic symbionts such as B. clausii et rel., Bifidobacteriaceae, 
Lactobacillaceae, B. subtilis et rel., Fusobacterium, and Cyanobacteria were largely subdominant. 
Opportunistic pathogens represented only a small fraction of the intestinal microbiota. Even if 
subjects under study showed a common trend when the ratio between the relative IF of major, minor 
and opportunistic components were considered, differences in the relative IF contribution of single 
probes were detectable and subject specific profiles were identified. For instance, subject n. 1 
showed a higher relative fluorescence for probes targeting major mutualistic symbionts and a lower 
relative fluorescence for minor mutualistic symbionts and opportunistic pathogens than subjects n. 4 
and 15. On the other hand, subjects n. 15 and 17 were characterized by a lower ratio 
Bacteroidetes/Firmicutes with respect to all the other subjects. Differences in relative IF 
contribution within samples could represent an useful approximation of differences in relative 
abundances of the targeted groups in the faecal microbiota, able to reflect compositional changes at 
high taxonomic level such as those occurring in the case of metabolic syndromes or IBD.   
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5.3 Comparison of the two microarray approaches 
 
In order to compare the two diversity microarray approaches presented here (HITChip and HTF-
Microb.Array), the fecal microbiota of five of the centenarians involved in the “Centenarians 
project” was analysed also with the HTF-Microb.Array tool. Because of the differences in the 
design of the two arrays, several approximation, described in details in the Results section, has been 
done to make the results as comparable as possible. The obtained profiles showed an overall 
similarity, with the exception of the underestimation of the Clostridium cluster XIVa and the 
overestimation of the Fusobacteria contribution in the HTF-Microb.Array. The underestimation of 
the Clostridium cluster XIVa may be due to the fact that in the HTF-Microb.Array this cluster is 
represented by only one probes, whereas in the HITChip the contribution of each cluster is 
calculated as the sum of all the probes hybridizing with members of that cluster. This problem may 
be solved by splitting the Clostridium cluster XIVa in several probes as it was done with the 
Clostridium cluster IV. 
With the correction of these deficiencies, the HTF-Microb.Array may represent a fast tool for the 
detection of high taxonomic level variations in the human gut microbiota, such as those occurring 
as a consequence of pathologies, metabolic syndromes or antibiotic/prebiotic treatments. However, 
caution must be taken when microarray based methods for the relative quantification of bacterial 
groups in complex microbial communities are used. In fact, biases are introduced at several levels 
of the experimental procedure: DNA extraction and purification, PCR amplification of the 16S 
rRNA gene, and interspecies variation of the rRNA gene copy number (Palmer et al, 2006). 
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6. 
CONCLUDING REMARKS 
 
 
The study presented here is focused on the application and comparison of two different microarray 
approaches for the characterization of the human gut microbiota: the HITChip and the HTF-
Microb.Array. The first has been developed and validated on a small group of patients by the 
Molecular Ecology Group, at the University of Wageningen, The Netherlands, whereas design, 
construction and validation of the second one are reported here. 
Here we confirmed that the HITChip is a powerful and reliable tool for the gut microbiota 
fingerprinting, and for the relative quantification of the microbiota components at different 
phylogenetic levels. The statistical analysis allowed us to obtain a large number of information 
about the impact of the aging process on the gut microbiota composition, diversity and variability, 
and to venture hypothesis about the functional role of these changes. 
Conversely, the validation of the HTF-Microb.Array on a group of healthy adults showed that this 
different microarray approach is a fast and sensitive tool for the high taxonomic level fingerprint of 
the human gut microbiota in terms of presence/absence of the principal groups. The evaluation of 
the relative abundance of the target groups on the bases of the relative fluorescence intensity probes 
response still has some hindrances, as demonstrated by comparing the HTF.Microb.Array and 
HITChip high taxonomic level fingerprints of the same centenarians. However, considering all the 
possible biases typical of the microarray technology (i.e. DNA extraction/purification, PCR, copy 
number variations), analysis of the fluorescence intensities may represent an useful approximation 
to estimate the relative abundance of the targets groups within each sample. Focusing the 
phylogenetic resolution at division, order and cluster levels, the HTF-Microb.Array showed the 
potential to characterize the high order taxonomic unbalances of the human gut microbiota 
associated with specific diseases. 
 
The study of the impact of the aging process on the human gut microbiota structure and 
functionality is of great importance in the perspective of both prevention and therapy of age-related 
diseases. Up to now, limited researches have been focused on this topic, and the available literature 
is poor and scattered. In the study presented here we explored the age related changes in both gut 
ecosystem composition, by using one of the newest diversity microarray approaches, the HITChip, 
and inflammatory status. The choice to focus our analysis on three age-groups (young adults, 
elderly and centenarians), instead of two (young adults and elderly, usually defined as “over-65”) 
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which is the usual approach, allowed us to provide a complete view of the age related changes in 
the gut microbiota composition during the whole adult life. 
Our results showed a remarkable similarity between the the gut microbiota composition of young 
adults and elderly, suggesting that this ecosystem is even more stable than expected during most of 
the human life in healthy conditions. On the contrary, a deep rearrangement in the gut bacterial 
ecosystem occurs in centenarians: the microbiota of this exceptionally old population showed 
alteration in the composition of the Firmicutes, especially those Clostridium clusters known to 
comprehend bacterial species with health promoting, i.e. anti-inflammatory, properties. Moreover, 
the gut microbiota of centenarians is enriched in those bacteria which are known to thrive in an 
inflamed environment, and probably nurture it, such as several members of the Proteobacteria. 
These observations, and the analysis of the correlation between the gut microbiota composition and 
several pro-inflammatory markers, suggest that the rearrangement in the composition may have a 
functional meaning in relation to the inflamm-aging process. In fact, changes in the gut microbiota 
composition may be caused by and/or contribute to the overall inflammatory status which is typical 
of the old age. The results presented here also suggest that the rearrangement of the gut bacterial 
ecosystem in terms of relative abundance of several groups of species may be part of the complex 
physiological remodelling which is at the base of the longevity of these exceptional individuals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Since people are going to be living longer and getting older, 
they'll just have to learn how to be babies longer.” 
 Andy Warhol, (1928-1987) 
 
 
Picture: Quirino Maestrello, “Reminescenze di mio padre”. 
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Appendix 1. Phylogenetically related groups target of the HTF-Microbi.Array.  
 
Probes Sub-probes 
Probe 
number 
Targeted bacteria 
Bacteroides/Prevotella   16 Bacteroides acidofaciens 
   Bacteroides barnesiae 
   Bacteroides caccae 
   Bacteroides coprocola 
   Bacteroides dorei 
   Bacteroides eggerthii 
   Bacteroides finegoldii 
   Bacteroides fragilis 
   Bacteroides helcogenes 
   Bacteroides intestinalis 
   Bacteroides massiliensis 
   Bacteroides nordii 
   Bacteroides ovatus 
   Bacteroides plebeius 
   Bacteroides splanchnicus 
   Bacteroides stercoris 
   Bacteroides thetaiotaomicron 
   Bacteroides uniformis 
   Bacteroides vulgatus 
   Prevotella albensis 
   Prevotella bivia 
   Prevotella brevis 
   Prevotella bryantii 
   Prevotella buccae 
   Prevotella buccalis 
   Prevotella corporis 
   Prevotella dentalis 
   Prevotella denticola 
   Prevotella disiens 
   Prevotella intermedia 
   Prevotella loescheii 
   Prevotella melaninogenica 
   Prevotella nigrescens 
   Prevotella oralis 
   Prevotella oris 
   Prevotella oulorum 
   Prevotella pallens 
   Prevotella ruminicola 
   Prevotella salivae 
   Prevotella shahii 
   Prevotella tannerae 
      Prevotella veroralis 
Clostridium cluster IV Ruminococcus bromii et 
rel. 
38 Clostridium leptum 
   Ruminococcus bromii 
 Ruminococcus albus et 
rel. 
39 Ruminococcus albus 
  Ruminococcus callidus 
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 A3 
    Ruminococcus flavefaciens 
 Oscillospira 
guillermondii et rel. 
40 Clostridium orbidescens 
  Clostridium viride 
   Oscillospira guillermondii 
   Papillibacter cinnaminovorans 
    Termitobacter aceticus 
 Faecalibacterium 
prausnitzii et rel. 
41 Acetanaerobacterium elongatum 
  Anaerofilum agile 
   Anaerofilum pentosovorans 
   Clostridium cellulosi 
   Clostridium methylpentosum 
   Ethanologenbacterium harbin 
   Eubacterium desmolans 
   Eubacterium siraeum 
   Faecalibacterium prausnitzii 
      Linmingia china 
Clostridium cluster IX  37 Acetonema longum 
   Acidaminococcus fermentans 
   Allisonella histaminiformis 
   Anaeroarcus burkinensis 
   Anaeroglobus geminatus 
   Anaeromusa acidaminophila 
   Anaerosinus glycerini 
   Anaerospora hongkongensis 
   Anaerovibrio lipolytica 
   Anaerovibrio lipolyticus 
   Centipeda periodontii 
   Dendrosporobacter quercicolus 
   Dialister invisus 
   Dialister pneumosintes 
   Megamonas hypermegale 
   Megasphaera cerevisiae 
   Megasphaera elsdenii 
   Megasphaera micrinuciformis 
   Mitsuokella jalaludinii 
   Mitsuokella multiacidus 
   Pectinatus cerevisiiphilus 
   Pectinatus frisingensis 
   Pectinatus portalensis 
   Phascolarctobacterium faecium 
   Propionispira arboris 
   Propionispora hippei 
   Propionispora vibrioides 
   Schwartzia succinivorans 
   Selenamonas flueggei 
   Selenomonas dianae 
   Selenomonas infelix 
   Selenomonas lacticifex 
   Selenomonas noxia 
   Selenomonas ruminantium 
   Selenomonas sputigena 
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 A4 
   Sporomusa acidovorans 
   Sporomusa aerivorans 
   Sporomusa malonica 
   Sporomusa ovata 
   Sporomusa paucivorans 
   Sporomusa silvacetica 
   Sporomusa sphaeroides 
   Sporomusa termitida 
   Succiniclasticum ruminis 
   Succinispira mobilis 
     Zymophilus paucivorans 
 Veillonella 20 Veillonella atypica 
   Veillonella caviae 
   Veillonella criceti 
   Veillonella dentocariosa 
   Veillonella dispar 
   Veillonella monpellierensis 
   Veillonella parvula 
   Veillonella ratti 
      Veillonella rodentium 
Clostridium cluster 
XIVa 
  
22 Acetitomaculum ruminis 
   Anaerostipes caccae 
   Bryantella formatexygens 
   Butyrivibrio crossotus 
   Butyrivibrio fibrisolvens 
   Butyrivibrio hungatei 
   Clostridium algidixylanolyticum 
   Clostridium aminophilum 
   Clostridium aminovalericum 
   Clostridium amygdalinum 
   Clostridium bolteae 
   Clostridium celerecrescens 
   Clostridium clostridiiforme 
   Clostridium coccoides 
   Clostridium fimetarium 
   Clostridium fusiformis 
   Clostridium hathewayi 
   Clostridium herbivorans 
   Clostridium horoticum 
   Clostridium hylemonae 
   Clostridium indolis 
   Clostridium methoxybenzovorans 
   Clostridium nexile 
   Clostridium phytofermentas 
   Clostridium polysaccharolyticum 
   Clostridium populeti 
   Clostridium proteoclasticum 
   Clostridium saccharolyticum 
   Clostridium scindens 
   Clostridium sphenoides 
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 A5 
   Clostridium symbiosum 
   Clostridium xylanolyticum 
   Clostridium xylanovorans 
   Desulfomaculum guttoideum 
   Dorea formicigerans 
   Eubacterium cellulosolvens 
   Eubacterium contortum 
   Eubacterium eligens 
   Eubacterium hallii 
   Eubacterium oxidoreducens 
   Eubacterium pectinii 
   Eubacterium plexicaudatum 
   Eubacterium ramulus 
   Eubacterium ruminantium 
   Eubacterium uniforme 
   Eubacterium ventrosum 
   Eubacterium xylanophilum 
   Hespellia porcina 
   Hespellia stercorisuis 
   Johnsonella ignava 
   Lachnobacterium bovis 
   Lachnospira multiparus (multipara) 
   Lachnospira pectinoschiza 
   Parasporobacterium paucivorans 
   Pseudobutyrivibrio ruminis 
   Pseudobutyrivibrio xylanovorans 
   Roseoburia cecicola 
   Roseoburia intestinalis 
   Ruminococcus gnavus 
   Ruminococcus lactaris 
   Ruminococcus torques 
   Ruminococcus hansenii 
   Ruminococcus hydrogenotrophicus 
   Ruminococcus obeum 
   Ruminococcus productus 
   Ruminococcus schinkii 
   Shuttleworthia satelles 
   Sporobacterium olearium 
     Syntrophococcus sucromutans 
  Eubacterium rectale 19 Eubacterium rectale 
Bifidobacteriaceae   25B Bifidobacterium aerophilum 
   Bifidobacterium adolescentis 
   Bifidobacterium angolatum 
   Bifidobacterium animalis 
   Bifidobacterium asteroides 
   Bifidobacterium bifidum  
   Bifidobacterium boum 
   Bifidobacterium breve 
   Bifidobacterium catenolatum 
   Bifidobacterium choerinum 
   Bifidobacterium coryneforme 
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 A6 
   Bifidobacterium cuniculi 
   Bifidobacterium dentium 
   Bifidobacterium gallicum 
   Bifidobacterium gallinarum 
   Bifidobacterium indicum 
   Bifidobacterium magnum 
   Bifidobacterium merycicum 
   Bifidobacterium minimum 
   Bifidobacterium pseudocatenolatum 
   Bifidobacterium psychroaerophylum 
   Bifidobacterium pullorum 
   Bifidobacterium ruminantium 
   Bifidobacterium saeculare 
   Bifidobacterium scardovii 
   Bifidobacterium simiae 
   Bifidobacterium subtile 
   Bifidobacterium thermoacidophilum 
   Bifidobacterium thermophilum 
   Bifidobacterium urinalis 
   Gardnerella vaginalis 
   Metascardovia tsurumii 
   Parascardovia denticolens 
     Scardovia inopinata 
 
Bifidobacterium longum 
et rel. 
  
3 Bifidobacterium longum biovar 
infantis 
 
 
Bifidobacterium longum biovar 
longum 
  Bifidobacterium longum biovar suis 
    Bifidobacterium pseudolongum 
Lactobacillaceae   21B Lactobacillus acidifarinae 
   Lactobacillus acetotolerans 
   Lactobacillus acidophilus 
   Lactobacillus amylolyticus 
   Lactobacillus amylophilus 
   Lactobacillus amylotrophus 
   Lactobacillus amylovorus 
   Lactobacillus antrumi 
   Lactobacillus coleohominis 
   Lactobacillus crispatus 
   Lactobacillus delbrueckii 
   Lactobacillus fermentum 
   Lactobacillus fornicalis 
   Lactobacillus frumenti 
   Lactobacillus gallinarum 
   Lactobacillus gasseri 
   Lactobacillus gastricus 
   Lactobacillus gastricus 
   Lactobacillus hamsteri 
   Lactobacillus helveticus 
   Lactobacillus iners 
   Lactobacillus ingluviei 
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   Lactobacillus intestinalis 
   Lactobacillus jensenii 
   Lactobacillus johnosii 
   Lactobacillus kalixi 
   Lactobacillus kefiranofaciens 
   Lactobacillus kefirgranum 
   Lactobacillus kitasatonis 
   Lactobacillus kitasoi 
   Lactobacillus mucosae 
   Lactobacillus oris 
   Lactobacillus panis 
   Lactobacillus pontis 
   Lactobacillus psittaci 
   Lactobacillus reuteri 
   Lactobacillus secaliphilus 
   Lactobacillus sobrius 
   Lactobacillus suntoryeus 
   Lactobacillus thermotolerans 
   Lactobacillus ultunense 
   Lactobacillus vaginalis 
   Lactobacillus brevis 
   Lactobacillus buchneri 
   Lactobacillus faeni 
   Lactobacillus ferintoshensis 
   Lactobacillus ferraginis 
   Lactobacillus fructivorans 
   Lactobacillus hammesii 
   Lactobacillus hilgardii 
   Lactobacillus homohiochii 
   Lactobacillus kefiri 
   Lactobacillus lindneri 
   Lactobacillus namurensis 
   Lactobacillus parabrevis 
   Lactobacillus parabuchneri 
   Lactobacillus paraferraginis 
   Lactobacillus parakefiri 
   Lactobacillus sanfranciscensis 
   Lactobacillus spicheri 
   Lactobacillus vermiforme 
   Lactobacillus zymae 
   Lactobacillus backi 
   Lactobacillus bifermentas 
   Lactobacillus composti 
   Lactobacillus coryniformis 
   Lactobacillus curvatus 
   Lactobacillus durianis 
   Lactobacillus fuchuensis 
   Lactobacillus graminis 
   Lactobacillus harbinensis 
   Lactobacillus malfermentas 
   Lactobacillus oligofermentans 
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   Lactobacillus perolens 
   Lactobacillus rossii 
   Lactobacillus sakei 
   Lactobacillus siligionis 
   Lactobacillus suebicus 
   Lactobacillus vaccinostercus 
   Pediococcus acidilactici 
   Pediococcus damnosum 
   Pediococcus parvulus 
     Pediococcus pentosaceus 
 Lactobacillus plantarm et 
rel. 
33 Lactobacillus arizonensis 
  Lactobacillus collinoides 
   Lactobacillus crustorum 
   Lactobacillus farciminis 
   Lactobacillus kimchii 
   Lactobacillus letivazi 
   Lactobacillus mindensis 
   Lactobacillus paracollinoides 
   Lactobacillus paralimentarius 
   Lactobacillus paraplantarum 
   Lactobacillus plantarum 
    Lactobacillus versmoldensis 
 Lactobacillus casei et rel. 12 Lactobacillus casei 
   Lactobacillus manihotivorans 
   Lactobacillus pantheris 
   Lactobacillus paracasei 
   Lactobacillus rhamnosus 
   Lactobacillus sharpeae 
    Lactobacillus zeae 
 Lactobacillus salivarius 
et rel. 
14 Lactobacillus agilis 
  Lactobacillus algidus 
   Lactobacillus animalis 
   Lactobacillus aviarius 
   Lactobacillus cypricasei 
   Lactobacillus equi 
   Lactobacillus mali 
   Lactobacillus mobilis 
   Lactobacillus murinus 
   Lactobacillus nageli 
   Lactobacillus ruminis 
   Lactobacillus saerimmeri 
      Lactobacillus salivarius 
Bacillus clausii et rel.   32 Bacillus clausii 
   Bacillus gibsonii 
   Bacillus halodurans 
   Bacillus horikoshii 
   Bacillus okuhidensis 
   Bacillus racemilacticus 
   Sporolactobacillus inulinus 
   Sporolactobacillus laevis 
   Sporolactobacillus laevolactis 
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   Sporolactobacillus myxolacticus 
   Sporolactobacillus racemicus 
      Sporolactobacillus racemilacticus 
Bacillus subtilis et rel.   8 Bacillus amyloliquefaciens 
   Bacillus atrophaeus 
   Bacillus licheniformis 
   Bacillus mojavensis 
   Bacillus pumilus 
   Bacillus sonorensis 
   Bacillus subtilis 
     Bacillus vallismortis 
Fusobacterium   15 Fusobacterium canifelinum 
   Fusobacterium equinum 
   Fusobacterium gonidiaformans 
   Fusobacterium mortiferum 
   Fusobacterium naviforme 
   Fusobacterium necrogenes 
   Fusobacterium necrophorum 
   Fusobacterium nucleatum 
   Fusobacterium periodonticum 
   Fusobacterium russii 
   Fusobacterium simiae 
   Fusobacterium ulcerans 
    Fusobacterium varium 
Cyanobacteria   
42 UNICYANO probe (Castiglioni B et 
al., 2004) 
Clostridium cluster XI   36 Acidaminobacter hydrogenoformans 
   Alcaliphilus transvaalensis 
   Alkaliphilus metalliredigenes 
   Anaerococcus hydrogenalis 
   Anaerococcus lactolyticus 
   Anaerococcus octavius 
   Anaerococcus prevotii 
   Anaerococcus tetradius 
   Anaerococcus vaginalis 
   Anaerovorax odorimutans 
   Anoxynatronum sibericum 
   Caldanaerocella colombiensis 
   Caminicella sporogenes 
   Clostridium aceticum 
   Clostridium alcalibutyricum 
   Clostridium alcaliphilum 
   Clostridium aminobutyricum 
   Clostridium aminovorans 
   Clostridium bartlettii 
   Clostridium bifermentans 
   Clostridium elmenteitii 
   Clostridium filamentosum 
   Clostridium firmicoaceticum 
   Clostridium ghoni 
   Clostridium glycolicum 
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   Clostridium halophilum 
   Clostridium hastiforme 
   Clostridium hiranonis 
   Clostridium irregularis 
   Clostridium litorale 
   Clostridium litoseburense 
   Clostridium mangenotii 
   Clostridium mayombei 
   Clostridium paradoxum 
   Clostridium purinolyticum 
   Clostridium sordelli 
   Clostridium sticklandii 
   Clostridium subatlanticum 
   Clostridium thermoalcaliphilum 
   Clostridium ultunense 
   Eubacterium angustum 
   Eubacterium brachy 
   Eubacterium infirmum 
   Eubacterium minutum 
   Eubacterium nodatum 
   Eubacterium pyruvativorans 
   Eubacterium saphenum 
   Eubacterium sulci 
   Eubacterium tenue 
   Eubacterium yurii 
   Filifactor alocis 
   Filifactor villosus 
   Finegoldia magna 
   Frigovirgula patogoniensis 
   Fusibacter paucivorans 
   Gallicola barnesae 
   Guggenheimia bovis 
   Helcoccus kunzii 
   Micromonas micros 
   Natronincola histidinovorans 
   Peptoniphilus asaccharolyticus 
   Peptoniphilus indolicus 
   Peptoniphilus lacrimalis 
   Peptostreptococcus anaerobius 
   Peptostreptococcus hareii  
   Peptostreptococcus ivoricus 
   Peptostreptococcus micros 
   Pseudoramibacter alactolyticus 
   Soehngenia saccharolytica 
   Sporoanaerobacter acetigenes 
   Tepidibacter formicigenes 
   Tepidibacter thalassicus 
   Tindallia californiensis 
   Tindallia magadii 
     Tissierella praeacuta 
 Clostridium difficile 18 Clostridium difficile 
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Clostridium clusters I 
and II 
  35 Anaerobacter polyendosporus 
  Clostridium absonum 
   Clostridium acetireducens 
   Clostridium acetobutylicum 
   Clostridium acidisoli 
   Clostridium akagii 
   Clostridium algidicarnis 
   Clostridium argentinense 
   Clostridium aurantibutyricum 
   Clostridium autoethanogenum 
   Clostridium barati 
   Clostridium beijerinckii 
   Clostridium botulinum 
   Clostridium bowmanii 
   Clostridium butyricum 
   Clostridium cadaveris 
   Clostridium caliptrosporum 
   Clostridium carboxidivorans 
   Clostridium carnis 
   Clostridium celatum 
   Clostridium cellulovorans 
   Clostridium chartatabidum 
   Clostridium chauvoei 
   Clostridium chromoreductans 
   Clostridium cochlearium 
   Clostridium colicanis 
   Clostridium collagenovorans 
   Clostridium corinoforum 
   Clostridium diolis 
   Clostridium disporicum 
   Clostridium estertheticum 
   Clostridium fallax 
   Clostridium favososporum 
   Clostridium felsineum 
   Clostridium fragidicarnis 
   Clostridium frigoris 
   Clostridium gasigenes 
   Clostridium grantii 
   Clostridium haemolyticum 
   Clostridium histolyticum 
   Clostridium homopropionicum 
   Clostridium intestinalis 
   Clostridium kainantoi 
   Clostridium kluyveri 
   Clostridium lacusfrykellense 
   Clostridium laramiense 
   Clostridium limosum 
   Clostridium ljungdahlii 
   Clostridium longisporum 
   Clostridium magnum 
   Clostridium maleniminatum 
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   Clostridium neonatale 
   Clostridium novyi 
   Clostridium oceanicum 
   Clostridium paraputrificum 
   Clostridium pasqui 
   Clostridium pasteurianum 
   Clostridium peptidovorans 
   Clostridium proteolyticum 
   Clostridium proteolyticus 
   Clostridium puniceum 
   Clostridium putrefaciens 
   Clostridium putrificum 
   Clostridium quinii 
   Clostridium ragsdalei 
   Clostridium roseum 
   Clostridium saccharobutylicum 
  
 
Clostridium 
saccharoperbutylacetonicum 
   Clostridium sardiniensis 
   Clostridium sartagoformum 
   Clostridium scatologenes 
   Clostridium septicum 
   Clostridium sporogenes 
   Clostridium subterminale 
   Clostridium tertium 
   Clostridium tetani 
   Clostridium tetanomorphum 
   Clostridium thermopalmarium 
   Clostridium thiosulfatireducens 
   Clostridium tunisiense 
   Clostridium tyrobutyricum 
   Clostridium uliginosum 
   Clostridium vincentii 
   Eubacterium budayi 
   Eubacterium combesii 
   Eubacterium moniliforme 
   Eubacterium multiforme 
   Eubacterium nitritogenes 
   Eubacterium tarantellus 
   Sarcina maxima 
     Sarcina ventriculi 
 Clostridium perfringens 17 Clostridium perfringens 
Enterococcus faecalis 
et rel. 
  9 Enterococcus caccae 
  Enterococcus faecalis 
   Enterococcus haemoperoxidus 
   Enterococcus moraviensis 
   Enterococcus rottae 
    Enterococcus silesiacus 
Enterococcus faecium 
et rel. 
  10 Enterococcus azikeevi 
  Enterococcus canis 
   Enterococcus durans 
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   Enterococcus faecium 
   Enterococcus hirae 
   Enterococcus mundtii 
   Enterococcus porcinus 
   Enterococcus pseudoavium 
   Enterococcus ratti 
   Enterococcus sanguinicola 
      Enterococcus villorum 
Bacillus cereus et rel.   7 Bacillus anthracis 
   Bacillus cereus 
   Bacillus mycoides 
   Bacillus pseudomycoides 
   Bacillus thuringensis 
     Bacillus weihenstephanenis 
Enterobacteriaceae  23B Citrobacter amalonaticus 
   Citrobacter farmeri 
   Citrobacter koseri 
   Citrobacter rodentium 
   Citrobacter sedlakii 
   Enterobacter cowanii 
   Escherichia albertii 
   Escherichia coli 
   Escherichia fergusonii 
   Escherichia senegalensis 
   Escherichia vulneri 
   Hafnia alvei 
   Photorabdus luminescens 
   Roultella planticola 
   Salmonella agona 
   Salmonella blockley 
   Salmonella bongori 
   Salmonella bovis 
   Salmonella chingola 
   Salmonella dublin 
   Salmonella enterica 
   Salmonella enteritidis 
   Salmonella give 
   Salmonella houten 
   Salmonella matopeni 
   Salmonella paratyphi 
   Salmonella shomron 
   Salmonella typhi 
   Salmonella typhimurium 
   Salmonella waycross 
   Salmonella weltevreden 
   Shigella boydii 
   Shigella dysenteriae 
   Shigella flexneri 
      Shigella sonnei 
Yersinia enterocolitica 
et rel. 
  4 Yersinia aldovae 
  Yersinia aleksiciae 
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   Yersinia bercovieri 
   Yersinia enterocolitica 
   Yersinia frederiksenii 
   Yersinia intermedia 
   Yersinia kristensenii 
   Yersinia pestis 
   Yersinia pseudotubercolosis 
   Yersinia massiliensis 
   Yersinia mollaretii 
   Yersinia rohdei 
    Yersinia ruckerii 
Proteus   5 Proteus hauseri 
   Proteus mirabilis 
   Proteus myxofaciens 
   Proteus penneri 
     Proteus vulgaris 
Campylobacter   6 Campylobacter coli 
   Campylobacter concisus 
   Campylobacter curvus 
   Campylobacter faecalis 
   Campylobacter fetus subsp fetus 
   Campylobacter fetus subsp venerealis 
   Campylobacter gracilis 
   Campylobacter helveticus 
   Campylobacter hominis 
   Campylobacter hyoilei 
   Campylobacter hyointestinalis 
   Campylobacter insulaenigrae 
   Campylobacter jejuni 
   Campylobacter lanienae 
   Campylobacter lari 
   Campylobacter mucosalis 
   Campylobacter rectus 
   Campylobacter showae 
   Campylobacter sporotum 
      Campylobacter upsaliensis 
 
Appendices 
 
 A15 
Appendix 2.  HTF-Microbi.Array probe list. Table of the 30 designed probe pairs.  
Sequences (5’ -> 3’) for both DS and CP are reported, as well as major thermodynamic parameters 
(melting temperature, length, number of degenerated bases) 
 
 
Table A2.1. Sequences (5’ -> 3’) for each discriminating probes (DS). In bold, the discriminating 
nucleotide. 
 
Zip 
code 
Probe  Name Discriminating oligo (DS) 
3 
Bifidobacterium 
longum et rel. 
GTATGGGATGGGGTCGCGTCCTATCAGCTTGAC 
4 
Yersinia enterocolitica 
et rel. 
GAGTAGGGCTACACACGTGCTACAATGGCAGATACAAAGT 
5 Proteus et rel. GGTCTTGAACCGTGGCTTCTGGAGCTAACGCGTTAAA 
6 Campylobacter GCTAGTTGGTRAGGTAATGGCTTACCAAGGCTATGACGCWTAA 
7 Bacillus cereus et rel. ACTCTGTTGTTAGGGAAGAACAAGTGCTAGTTGAATAAGC 
8 Bacillus subtilis et rel. GCAGCGAAACCGCGAGGTTAAGCCAATCCCAC 
9 
Enterococcus faecalis 
et rel. 
GGAAGTACAACGAGTCGCTAGACCGCGAGGTCAT 
10 
Enterococcus faecium 
et rel. 
CGCTTCTTTTTCCACCGGAGCTTGCTCCACCG 
12 
Lactobacillus casei et 
rel. 
GGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGC 
14 
Lactobacillus salivarius 
et rel. 
GTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAA 
15 Fusobacterium GGGGAAGCCAGCYTACTGGACAGATACTGACGCTRAA 
16 Bacteroides/Prevotella CATTAAGYATYCCACCTGGGGAGTACGCCGGCAAC 
17 
Clostridium perfringens 
et rel. 
CTACACTTGACATCCCTTGCATTACTCTTAATCGAGGAAA 
18 
Clostridium difficile et 
rel. 
GAACGCTGGCGGCGTGCCTAACACATGCAAGTT 
19 
Eubacterium rectale et 
rel. 
CATTGCTTCTCGGTGCCGTCGCAAACGCAG 
20 Veillonella GGTGGGAACTCATGAGAGACTGCCGCAGACAAT 
25B Bifidobacteriaceae TAGGGGAGACTGGAATTCCCGGTGTAACGGTGGAATGT 
23B Enterobacteriaceae GGGACCTTCGGGCCTCTTGCCATCGGATGT 
21B Lactobacillaceae AAGAACACCAGTGGCGAAGGCGGCTSTCTGGT 
22 
Clostridium cluster 
XIVa 
CCGCGTGAGYGAAGAAGTATTTCGGTATGTAAAGCTCTA 
32 Bacillus clausii et rel. CCTAGAGATAGGGCTTTCCCCTTCGGGGGACAA 
33 
Lactobacillus 
plantarum et rel. 
CTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGA 
35 
Clostridium cluster I 
and II 
GCGTAAAGGGWGCGTAGGYGGATNTTTAAGTGRGATGTGAAATA 
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36 Clostridium cluster XI CGATGAAGGCCTTCGGGTCGTAAAGCTCTGTCC 
37 Clostridium cluster IX GAGCGAACGGGATTAGATACCCCGGTAGTCCTG 
38 
Cl IV: Ruminococcus 
bromii et rel. 
GAACCTTACCAGGTCTTGACATCCAACTAACGAAGTAGAGATRCA 
39 
Cl IV: Ruminococcus 
albus et rel. 
GAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACAT 
40 
Cl IV: 
Faecalibacterium 
prausnizii et rel.  
GTAAAGGGAGCGCAGGCGGGANGGCAAGTT 
41 
Cl IV: Oscillospira 
guillermondii et rel. 
GGCYTTCGGGTTGTAAACTTCTTTTAAGGGGGAAGARCAGAA 
42 Cyanobacteria CCCAGACTCCTACGGGAGGCAGCAGTG 
 
 
 
Table A2.2. Sequences (5’ -> 3’) for each common probes (CP). In bold, the discriminating 
nucleotide. 
 
Zip 
code 
Probe Name Common probe (CP) 
3 
Bifidobacterium longum 
et rel. 
GGCGGGGTAACGGCCNACCGTGGCT 
4 
Yersinia enterocolitica 
et rel. 
GAAGCGAACTCGCGAGAGCAAGCGGACC 
5 Proteus et rel. TCGACCGCCTGGGGAGTACGGCCGC 
6 Campylobacter CTGGTCTGAGAGGATGATCAGTCACACTGGAACTGAG 
7 Bacillus cereus et rel. TGGCACCTTGACGGTACCTAACCAGAAAGCCACGG 
8 Bacillus subtilis et rel. AAATCTGTTCTCAGTTCGGATCGCAGTCTGCAACTCGA 
9 
Enterococcus faecalis et 
rel. 
GCAAATCTCTTAAAGCTTCTCTCAGTTCGGATTGCAGGCTG 
10 
Enterococcus faecium et 
rel. 
GAAAAAGARGAGTGGCGAACGGGTGAGTAACACGTGG 
12 
Lactobacillus casei et 
rel. 
AGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAG 
14 
Lactobacillus salivarius 
et rel. 
GCGGCTCTCTGGTCTGTAACTGACGCTGAGG 
15 Fusobacterium GCGCGAAAGCGTGGGTAGCAAACAGGATTAGATACC 
16 Bacteroides/Prevotella GGTGAAACTCAAAGGAATTGACGGGGGCCCGC 
17 
Clostridium perfringens 
et rel. 
TCCCTTCGGGGACAAGGTGACAGGTGGTGCAT 
18 
Clostridium difficile et 
rel. 
GAGCGATTTACTTCGGTAAAGAGCGGCGGACGG 
19 
Eubacterium rectale et 
rel. 
TAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTC 
20 Veillonella GCGGAGGAAGGCGGGGATGACGTCAAATC 
25B Bifidobacteriaceae GTAGATATCGGGAAGAACACCAATGGCGAAGGCAGGTCT 
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23B Enterobacteriaceae GCCCAGATGGGATTAGCTWGTWGGTGGGGTAACG 
21B Lactobacillaceae CTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGC 
22 
Clostridium cluster 
XIVa 
TCAGCAGGGAAGAWAATGACGGTACCTGACTAAGAAGCNC 
32 Bacillus clausii et rel. AGTGACAGGTGGTGCATGGTTGTCGTCAGCTCG 
33 
Lactobacillus plantarum 
et rel. 
GTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAGGCTG 
35 
Clostridium cluster I 
and II 
CCCGGGCTYAACYTGGGTGCTGCATTYCAAAC 
36 Clostridium cluster XI TAARGGAAGAWAATGACGGTACYTTAGGAGGAAGCCCCG 
37 Clostridium cluster IX GCCGTAAACGATGGRTACTAGGTGTAGGAGGTATCG 
38 
Cl IV: Ruminococcus 
bromii et rel. 
TTAGGTGCCCTTCGGGGAAAGKTGAGACAGGTG 
39 
Cl IV: Ruminococcus 
albus et rel. 
CAGTGGCGAAGGCGGCTTACTGGGCTTTAACTG 
40 
Cl IV: Faecalibacterium 
prausnizii et rel.  
GGAAGTGAAATCTATGGGCTCAACCCATGAACTGCTTTCAAAAC 
41 
Cl IV: Oscillospira 
guillermondii et rel. 
GACGGTACCCCTTGAATAAGCCACGGCTAACTACG 
42 Cyanobacteria GGGAATTTTCCGCAATGGGCGAAAGCCTGACGG 
 
 
 
Table A2.3. Major thermodynamic parameters of each probe pair (DS and CP): length, melting 
temperature (Tm), number of degenerated bases (Deg).  
 
Zip 
code 
Probe  Name 
DS Length 
(nt) 
CP Length 
(nt) 
Tm 
DS 
Tm CP Deg DS Deg CP 
3 
Bifidobacterium longum 
et rel. 
33 25 68.1 68.3 0 1 
4 
Yersinia enterocolitica 
et rel. 
40 28 67.6 67.2 0 0 
5 Proteus et rel. 37 25 67.8 69.2 0 0 
6 Campylobacter 43 37 67.9 67.8 2 0 
7 Bacillus cereus et rel. 40 35 64.5 69.1 0 0 
8 Bacillus subtilis et rel. 32 38 68.2 66.6 0 0 
9 
Enterococcus faecalis et 
rel. 
34 41 68 67.5 0 0 
10 
Enterococcus faecium et 
rel. 
32 37 68.2 68.3 0 1 
12 
Lactobacillus casei et 
rel. 
38 36 67.7 67.9 0 0 
14 
Lactobacillus salivarius 
et rel. 
40 31 65.5 68.3 0 0 
15 Fusobacterium 37 36 68.9 67.9 2 0 
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16 Bacteroides/Prevotella 35 32 69.1 68.2 2 0 
17 
Clostridium perfringens 
et rel. 
40 32 64.5 68.2 0 0 
18 
Clostridium difficile et 
rel. 
33 33 68.1 68.1 0 0 
19 
Eubacterium rectale et 
rel. 
30 42 67.1 67.4 0 0 
20 Veillonella 34 29 66.9 67.2 0 0 
25B Bifidobacteriaceae 38 39 68.8 68.7 0 0 
23B Enterobacteriaceae 30 34 68.5 68 0 2 
21B Lactobacillaceae 32 36 68.2 69 1 0 
22 
Clostridium cluster 
XIVa 
39 40 66.1 68.1 1 2 
32 Bacillus clausii et rel. 33 33 68.1 68.1 0 0 
33 
Lactobacillus plantarum 
et rel. 
38 45 67.7 67.3 0 0 
35 
Clostridium cluster I 
and II 
44 32 67.8 67.6 4 3 
36 Clostridium cluster XI 33 39 68.1 67.6 0 3 
37 Clostridium cluster IX 33 36 68.1 67.3 0 1 
38 
Cl IV: Ruminococcus 
bromii et rel. 
45 33 67.7 67.5 1 1 
39 
Cl IV: Ruminococcus 
albus et rel. 
46 33 67.2 68.1 0 0 
40 
Cl IV: Faecalibacterium 
prausnizii et rel.  
30 44 67.8 67.3 1 0 
41 
Cl IV: Oscillospira 
guillermondii et rel. 
42 35 67.4 67.9 2 0 
42 Cyanobacteria 27 33 67.3 68.1 0 0 
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Appendix 3. Results of the probe specificity tests.  
Twenty-eight bacterial DNA targets were chosen to validate the probe pairs. For each DNA 
analyzed are reported: probe pair showing significant positive signals, SNRs, SNRns (see main text 
for acronym definitions). Results are reported for each duplicate experiment. Where needed (i.e. 
more than one probe pair was present), data are the average of the positive signals (for both SNR 
and P values) 
 
Test Positive signal SNR ns SNR s 
P values 
specificity 
Bacteroides fragilis ATCC25285 Bacteroides/Prevotella 
0.85 30.81 9.35E-05 
0.53 21.45 7.39E-04 
Bacteroides thetaiotaomicrom 
ATCC29143 
Bacteroides/Prevotella 
0.45 61.44 2.56E-04 
1.66 347.24 9.10E-06 
Lactobacillus gasseri DSM20243 Lactobacillaceae 
0.3 5.58 4.98E-03 
1.56 20.59 6.58E-03 
Prevotella melaninogenica 
ATCC25845 
Bacteroides/Prevotella 
1.54 480.24 6.02E-08 
0.9 266.63 3.74E-09 
Bacillus subtilis DSM704 Bacillus subtilis et rel. 
7.93 637.39 1.56E-09 
5.62 350.1 1.47E-05 
Escherichia coli ATCC11105 Enterobacteriaceae 
3.27 555.04 8.65E-08 
2.59 222.39 4.50E-07 
Proteus mirabilis DSM4479 
Proteus et rel., 2.42 703.22 7.74E-09 
Enterobacteriaceae 2.03 497.1 1.97E-09 
Bifidobacterium  bifidum 
DSM20456 
Bifidobacteriaceae 
2.67 289.39 4.78E-11 
2.23 407.1 2.40E-08 
Lactobacillus  casei DSM20011 
Lactobacillaceae, 2.59 125.13 1.01E-04 
Lactobacillus casei et rel. 2.26 134.78 5.92E-04 
Yersinia enterocolitica 
Yersinia enterocolitica et 
rel., Enterobacteriaceae 
1.53 231.33 1.01E-05 
2.89 340.2 1.61E-06 
Bacillus cereus DSM31 Bacillus cereus et rel. 
2.83 193.85 1.53E-06 
2.49 196.82 4.16E-03 
Bifidobacterium  adolescentis 
ATCC15703 
Bifidobacteriaceae 
4.1 732.95 3.95E-10 
2.9 338.59 5.59E-07 
Lactobacillus ramnosus 
DSM20021 
Lactobacillaceae, 2.4 101.76 1.41E-03 
Lactobacillus casei et rel. 4.23 177.7 4.62E-07 
Lactobacillus delbrueckii 
DSM20074 
Lactobacillaceae 
3.77 210.11 2.24E-08 
3.1 121.93 6.27E-08 
Lactobacillus pentosus DSM20314 Lactobacillaceae 
3.05 131.65 4.58E-09 
1.63 58.3 5.32E-07 
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Lactobacillus  acidophilus 
DSM20079 
Lactobacillaceae 
2.39 68.49 8.70E-05 
2.66 78.5 5.88E-06 
Lactobacillus reuteri DSM20016 Lactobacillaceae 
3.17 150.57 4.66E-09 
1.74 83.6 1.98E-07 
Lactobacillus  plantarum 
DSM21074 
Lactobacillus  plantarum 
et rel., Lactobacillaceae 
2.12 197.32 3.79E-09 
2.09 148.35 2.77E-08 
Clostridium  difficile 
ATCCBAA1382 
Clostridium cluster XI, 1.12 238.87 4.88E-04 
Clostridium difficile et rel. 0.8 126.38 1.96E-03 
Campylobacter jejuni ATCC33292 Campylobacter  
0.7 19.89 5.29E-03 
0.91 28.44 5.69E-03 
Veillonella parvula ATCC10790 
Veillonella, 1.12 205.66 1.57E-04 
Clostridium cluster IX 0.99 140.95 1.39E-04 
Bifidobacterium breve DSM20091 Bifidobacteriaceae 
2.22 570.01 6.22E-05 
1.69 289.07 2.72E-04 
Bifidobacterium  longum 
ATCC15707 
Bifidobacterium longum et 
rel., Bifidobacteriaceae 
1.76 341.94 1.64E-03 
0.66 134.86 4.26E-02 
Ruminococcus productus ATCC 
23340 
Clostridium cluster XIVa 
0.64 4.21 1.41E-03 
1.06 17.16 1.24E-06 
Lactobacillus salivarius SV2 
Lactobacillus salivarius et 
rel., Lactobacillaceae 
0.89 12.23 4.34E-04 
0.65 7.27 2.69E-05 
Enterococcus faecalis 
ATCC700802 
Enterococcus faecalis et 
rel. 
3.12 306.51 1.09E-03 
2.27 217.16 6.56E-03 
Clostridium leptum DSM73 
Ruminocuccos bromii et 
rel.,  
Clostridium cluster IV 
2.28 88.89 5.52E-07 
1.13 39.86 2.00E-07 
Ruminococcus albus DSM20455 
Ruminocuccos albus et 
rel., 
Clostridium cluster IV 
1.46 47.05 2.50E-07 
1.41 32.01 4.37E-06 
 
 
 
 
 
